<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1351" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1351/" /><meta name="ncbi_pagename" content="Hereditary Hemorrhagic Telangiectasia - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Hereditary Hemorrhagic Telangiectasia - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Hereditary Hemorrhagic Telangiectasia" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/02/02" /><meta name="citation_author" content="Jamie McDonald" /><meta name="citation_author" content="Reed E Pyeritz" /><meta name="citation_pmid" content="20301525" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1351/" /><meta name="citation_keywords" content="HHT" /><meta name="citation_keywords" content="Osler-Weber-Rendu Disease" /><meta name="citation_keywords" content="Osler-Weber-Rendu Disease" /><meta name="citation_keywords" content="HHT" /><meta name="citation_keywords" content="Endoglin" /><meta name="citation_keywords" content="Growth/differentiation factor 2" /><meta name="citation_keywords" content="Mothers against decapentaplegic homolog 4" /><meta name="citation_keywords" content="Serine/threonine-protein kinase receptor R3" /><meta name="citation_keywords" content="ACVRL1" /><meta name="citation_keywords" content="ENG" /><meta name="citation_keywords" content="GDF2" /><meta name="citation_keywords" content="SMAD4" /><meta name="citation_keywords" content="Hereditary Hemorrhagic Telangiectasia" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Hereditary Hemorrhagic Telangiectasia" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Jamie McDonald" /><meta name="DC.Contributor" content="Reed E Pyeritz" /><meta name="DC.Date" content="2017/02/02" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1351/" /><meta name="description" content="Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of multiple arteriovenous malformations (AVMs) that lack intervening capillaries and result in direct connections between arteries and veins. The most common clinical manifestation is spontaneous and recurrent nosebleeds (epistaxis) beginning on average at age 12 years. Telangiectases (small AVMs) are most evident on the lips, tongue, buccal mucosa, face, chest, and fingers. The average age of onset is generally later than epistaxis, but may be during childhood. Large AVMs often cause symptoms when they occur in the lungs, liver, or brain; complications from bleeding or shunting may be sudden and catastrophic. Approximately 25% of individuals with HHT have GI bleeding, which most commonly begins after age 50 years." /><meta name="og:title" content="Hereditary Hemorrhagic Telangiectasia" /><meta name="og:type" content="book" /><meta name="og:description" content="Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of multiple arteriovenous malformations (AVMs) that lack intervening capillaries and result in direct connections between arteries and veins. The most common clinical manifestation is spontaneous and recurrent nosebleeds (epistaxis) beginning on average at age 12 years. Telangiectases (small AVMs) are most evident on the lips, tongue, buccal mucosa, face, chest, and fingers. The average age of onset is generally later than epistaxis, but may be during childhood. Large AVMs often cause symptoms when they occur in the lungs, liver, or brain; complications from bleeding or shunting may be sudden and catastrophic. Approximately 25% of individuals with HHT have GI bleeding, which most commonly begins after age 50 years." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1351/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/hht/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1351/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE89FE00DFC8546100000000049E0239.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1351_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1351_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/deafness-overview/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hlrcc/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1351_"><span class="title" itemprop="name">Hereditary Hemorrhagic Telangiectasia</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: HHT, Osler-Weber-Rendu Disease</div><p class="contrib-group"><span itemprop="author">Jamie McDonald</span>, MS, CGC and <span itemprop="author">Reed E Pyeritz</span>, MD, PhD, FACMG.</p><a data-jig="ncbitoggler" href="#__NBK1351_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1351_ai__"><div class="contrib half_rhythm"><span itemprop="author">Jamie McDonald</span>, MS, CGC<div class="affiliation small">Co-Director, HHT Clinic<br />Departments of Radiology and Pathology<br />University of Utah Medical Center<br />Salt Lake City, Utah<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.hatu.csh@dlanodcm.eimaj" class="oemail">ude.hatu.csh@dlanodcm.eimaj</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Reed E Pyeritz</span>, MD, PhD, FACMG<div class="affiliation small">Departments of Medicine and Genetics<br />Perelman School of Medicine at the University of Pennsylvania<br />Co-Director, HHT Center<br />Hospital of the University of Pennsylvania<br />Philadelphia, Pennsylvania<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.nnepu.shpu@ztireyp.deer" class="oemail">ude.nnepu.shpu@ztireyp.deer</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">June 26, 2000</span>; Last Update: <span itemprop="dateModified">February 2, 2017</span>.</p><p><em>Estimated reading time: 36 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="hht.Summary" itemprop="description"><h2 id="_hht_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of multiple arteriovenous malformations (AVMs) that lack intervening capillaries and result in direct connections between arteries and veins. The most common clinical manifestation is spontaneous and recurrent nosebleeds (epistaxis) beginning on average at age 12 years. Telangiectases (small AVMs) are most evident on the lips, tongue, buccal mucosa, face, chest, and fingers. The average age of onset is generally later than epistaxis, but may be during childhood. Large AVMs often cause symptoms when they occur in the lungs, liver, or brain; complications from bleeding or shunting may be sudden and catastrophic. Approximately 25% of individuals with HHT have GI bleeding, which most commonly begins after age 50 years.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of HHT is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with three or more of the following clinical features: epistaxis, mucocutaneous telangiectases, visceral AVMs, and/or a family history of HHT. Identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ACVRL1</i>, <i>ENG</i>, <i>GDF2</i>, or <i>SMAD4</i> establishes the diagnosis if clinical features are inconclusive.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Nosebleeds are treated with humidification, nasal lubricants, hemostatic products, laser ablation, sclerotherapy, nasal closure, and oral or topical medications. GI bleeding is treated with iron replacement therapy and (if needed) endoscopic ablation, surgical resection of bleeding sites, and/or medical therapy. Pulmonary AVMs with a feeding vessel 1 mm or greater in diameter require consideration of occlusion. Cerebral AVMs are treated, when indicated by location or symptoms, by surgery, embolotherapy, and/or stereotactic radiosurgery. Symptomatic hepatic AVMs are managed medically; liver transplantation is recommended for individuals who do not respond to medical therapy and who develop hepatic failure. Women with HHT considering pregnancy are screened and treated for pulmonary and cerebral AVMs; pulmonary AVMs discovered during pregnancy are treated during the second trimester. Iron replacement is preferred for anemia, but transfusion of packed red blood cells may be necessary for symptomatic anemia.</p><p><i>Prevention of secondary complications:</i> When pulmonary AVMs are present or suspected, antibiotic prophylaxis for dental and invasive procedures and a filter on intravenous lines to prevent air bubbles from being inadvertently infused is recommended.</p><p><i>Surveillance:</i> Annual evaluations for anemia; supine and sitting pulse-oximetry every one to two years during childhood; evaluation for pulmonary AVMs every five years with contrast echocardiography by age ten years; head MRI in infancy and then rescreening for cerebral AVMs by brain MRI after puberty; periodic screening for gastrointestinal polyps and malignant change in persons with juvenile polyps.</p><p><i>Agents/circumstances to avoid:</i> Vigorous nose blowing; lifting heavy objects; straining during bowel movements; electric or chemical cautery for nosebleeds; anticoagulant and anti-inflammatory agents (including aspirin) in individuals with significant nose or GI bleeding; scuba diving unless contrast echocardiography within the last five years was negative for evidence of a right to left shunt; liver biopsy.</p><p><i>Evaluation of relatives at risk:</i> Molecular genetic testing is offered to at-risk family members if the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the family. If the pathogenic variant in the family is not known, at-risk family members should be evaluated for signs and symptoms of HHT and screening should be offered to at-risk family members if the diagnosis cannot be ruled out.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>HHT is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner with considerable <a class="def" href="/books/n/gene/glossary/def-item/intrafamilial-variability/">intrafamilial variability</a>. Most individuals have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Each child of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and the sibs of most probands are at a 50% risk of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Prenatal testing is possible for pregnancies at increased risk if the pathogenic variant in the family is known.</p></div></div><div id="hht.Diagnosis"><h2 id="_hht_Diagnosis_">Diagnosis</h2><div id="hht.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Hereditary hemorrhagic telangiectasia (HHT) <b>should be considered</b> in an individual with any of the following features:</p><ul><li class="half_rhythm"><div><b>Nosebleeds (epistaxis).</b> Spontaneous and recurrent; night-time nosebleeds heighten the concern for HHT.</div></li><li class="half_rhythm"><div><b>Mucocutaneous telangiectases</b> (small blanchable red spots that are focal dilatations of post-capillary venules or delicate, lacy red vessels composed of markedly dilated and convoluted venules). Multiple, at characteristic sites, including lips, oral cavity, fingers, and nose. Transillumination of the digits is helpful for detecting vascular lesions not evident on the skin [<a class="bk_pop" href="#hht.REF.mohler.2009.356">Mohler et al 2009</a>].</div></li><li class="half_rhythm"><div><b>Visceral arteriovenous malformation (AVM).</b> An arteriovenous malformation lacks capillaries and consists of direct connections between arteries and veins. AVMs may be pulmonary, cerebral, hepatic, spinal, gastrointestinal, or pancreatic.</div></li><li class="half_rhythm"><div><b>Family history.</b> A <a class="def" href="/books/n/gene/glossary/def-item/first-degree-relative/">first-degree relative</a> in whom HHT has been diagnosed</div></li></ul></div><div id="hht.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>According to published consensus clinical diagnostic criteria, the diagnosis of HHT is considered "confirmed" in an individual with <b>three or more</b> of the <a href="#hht.Suggestive_Findings">above features</a>. The diagnosis of HHT is considered "suspected" in an individual with <b>two</b> of the above features [<a class="bk_pop" href="#hht.REF.shovlin.2000.66">Shovlin et al 2000</a>]. Identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of the genes listed in <a class="figpopup" href="/books/NBK1351/table/hht.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="fighhtTmoleculargenetictestingusedin" rid-ob="figobhhtTmoleculargenetictestingusedin">Table 1</a> establishes the diagnosis if clinical features are inconclusive.</p><p>Note: The application of these clinical diagnostic criteria to children at risk for HHT can be misleading. Symptoms and signs of HHT generally develop during childhood and adolescence; epistaxis, telangiectases, and symptoms of visceral AVMs are frequently absent in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children (see <a href="#hht.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a>).</p><p>Molecular genetic testing approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> can be considered. Sequence analysis of <i>ACVRL1</i> and <i>ENG</i> can be performed first. Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis of <i>ACVRL1</i> and <i>ENG</i> can be done next if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div><ul><li class="half_rhythm"><div>Sequence analysis of <i>SMAD4</i> should be considered first in any person with HHT and intestinal polyps. <i>SMAD4</i> <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> should also be considered in symptomatic individuals in whom no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified through sequence analysis and <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>ACVRL1</i> and <i>ENG</i>.</div></li><li class="half_rhythm"><div>Sequence analysis of <i>GDF2</i> could be considered for symptomatic individuals in whom no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified in <i>ACVRL1, ENG</i>, or <i>SMAD4</i> particularly if dermal telangiectases appear larger than pinhead-pinpoint size and are not limited to the hands, mouth, and face.</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>ACVRL1</i>, <i>ENG, GDF2, SMAD4</i> and other genes of interest (see <a href="#hht.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included and the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of multigene panels vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes the genes in listed in <a class="figpopup" href="/books/NBK1351/table/hht.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="fighhtTmoleculargenetictestingusedin" rid-ob="figobhhtTmoleculargenetictestingusedin">Table 1</a>) fails to confirm a diagnosis in an individual with features of HHT. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="hht.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Hereditary Hemorrhagic Telangiectasia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1351/table/hht.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hht.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of HHT Attributed to Pathogenic Variants in This Gene</th><th id="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr><tr><th headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></th><th headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></th></tr></thead><tbody><tr><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ACVRL1</i></td><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25%-57%&#x000a0;<sup>5,&#x000a0;6</sup></td><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">90%&#x000a0;<sup>6</sup></td><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ENG</i></td><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">39%-59%&#x000a0;<sup>5,&#x000a0;6</sup></td><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">90%&#x000a0;<sup>6</sup></td><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GDF2</i></td><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3 individuals&#x000a0;<sup>8</sup></td><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%</td><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SMAD4</i></td><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%-2% <sup>6,&#x000a0;10</sup></td><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;99%&#x000a0;<sup>6</sup></td><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>11,&#x000a0;12</sup></td><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hht.TF.1.1"><p class="no_margin">See <a href="/books/NBK1351/#hht.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="hht.TF.1.2"><p class="no_margin">See <a href="#hht.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="hht.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="hht.TF.1.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications</p></div></dd><dt>5. </dt><dd><div id="hht.TF.1.5"><p class="no_margin">There is a slight preponderance of <i>ENG</i> pathogenic variants in North America (~50%) and in northern Europe [<a class="bk_pop" href="#hht.REF.brusgaard.2004.556">Brusgaard et al 2004</a>, <a class="bk_pop" href="#hht.REF.letteboer.2005.8">Letteboer et al 2005</a>, <a class="bk_pop" href="#hht.REF.schulte.2005.595">Schulte et al 2005</a>, <a class="bk_pop" href="#hht.REF.bossler.2006.667">Bossler et al 2006</a>, <a class="bk_pop" href="#hht.REF.prigoda.2006.722">Prigoda et al 2006</a>, <a class="bk_pop" href="#hht.REF.gedge.2007.258">Gedge et al 2007</a>] compared to <i>ACVRL1</i> pathogenic variants (~35%), and a greater preponderance of <i>ACVRL1</i> pathogenic variants in southern Europe [<a class="bk_pop" href="#hht.REF.lenato.2006.213">Lenato et al 2006</a>, <a class="bk_pop" href="#hht.REF.lesca.2006.598">Lesca et al 2006</a>, <a class="bk_pop" href="#hht.REF.olivieri.2007.820">Olivieri et al 2007</a>].</p></div></dd><dt>6. </dt><dd><div id="hht.TF.1.6"><p class="no_margin">Sequence analysis of <i>ACVRL1, ENG</i>, and <i>SMAD4</i> identifies pathogenic variants in approximately 75% of individuals with HHT [<a class="bk_pop" href="#hht.REF.bossler.2006.667">Bossler et al 2006</a>, <a class="bk_pop" href="#hht.REF.prigoda.2006.722">Prigoda et al 2006</a>, <a class="bk_pop" href="#hht.REF.gedge.2007.258">Gedge et al 2007</a>, <a class="bk_pop" href="#hht.REF.richardsyutz.2010.61">Richards-Yutz et al 2010</a>]. There are no common pathogenic variants, and sequence variants interpreted to be of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> are particularly common.</p></div></dd><dt>7. </dt><dd><div id="hht.TF.1.7"><p class="no_margin">The use of <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> in addition to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> increases the detection rate by approximately 10% for <i>ACVRL1</i>- and <i>ENG</i>-related HHT [<a class="bk_pop" href="#hht.REF.bossler.2006.667">Bossler et al 2006</a>, <a class="bk_pop" href="#hht.REF.prigoda.2006.722">Prigoda et al 2006</a>, <a class="bk_pop" href="#hht.REF.mcdonald.2011b.335">McDonald et al 2011b</a>].</p></div></dd><dt>8. </dt><dd><div id="hht.TF.1.8"><p class="no_margin">Pathogenic variants in <i>GDF2</i> were identified in three individuals with features of HHT [<a class="bk_pop" href="#hht.REF.wooderchakdonahue.2013.530">Wooderchak-Donahue et al 2013</a>].</p></div></dd><dt>9. </dt><dd><div id="hht.TF.1.9"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available; however, one large deletion has been associated with juvenile polyposis and HHT [<a class="bk_pop" href="#hht.REF.wain.2014.588">Wain et al 2014</a>].</p></div></dd><dt>10. </dt><dd><div id="hht.TF.1.10"><p class="no_margin">Approximately 10% of those who test negative for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ACVRL1</i> and <i>ENG</i> [<a class="bk_pop" href="#hht.REF.gallione.2006.793">Gallione et al 2006</a>, <a class="bk_pop" href="#hht.REF.lesca.2006.598">Lesca et al 2006</a>, <a class="bk_pop" href="#hht.REF.prigoda.2006.722">Prigoda et al 2006</a>]</p></div></dd><dt>11. </dt><dd><div id="hht.TF.1.11"><p class="no_margin">One individual with signs of HHT and prominent pulmonary hypertension had a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>BMPR2</i> [<a class="bk_pop" href="#hht.REF.rigelsky.2008.2551">Rigelsky et al 2008</a>].</p></div></dd><dt>12. </dt><dd><div id="hht.TF.1.12"><p class="no_margin">Linkage analysis in one <a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a> suggests a 5.4-cm disease <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> interval on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 5 (HHT3) [<a class="bk_pop" href="#hht.REF.cole.2005.577">Cole et al 2005</a>]. Linkage analysis in another pedigree suggests a disease gene in a 7-Mb region on the short arm of chromosome 7 (7p14) (HHT4) [<a class="bk_pop" href="#hht.REF.bayraktoydemir.2006a.2155">Bayrak-Toydemir et al 2006a</a>]. Rare pedigrees are not linked to any of these loci, suggesting additional heterogeneity.</p></div></dd></dl></div></div></div></div></div><div id="hht.Clinical_Characteristics"><h2 id="_hht_Clinical_Characteristics_">Clinical Characteristics</h2><div id="hht.Clinical_Description"><h3>Clinical Description</h3><p>Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of multiple arteriovenous malformations (AVMs) that lack intervening capillaries and result in direct connections between arteries and veins. Small arteriovenous malformations are called telangiectases. The term AVM usually refers to the "large" telangiectases, greater than a few millimeters in diameter and sometimes up to several centimeters in diameter. The most common feature that brings individuals with HHT to medical attention are epistaxis (nosebleeds).</p><p><b>Epistaxis (nosebleeds).</b> The nasal mucosa is fragile and minor insults from drying air and repeated minor abrasions result in recurrent bleeding. Epistaxis has an average age of onset of approximately 12 years [<a class="bk_pop" href="#hht.REF.aassar.1991.977">Aassar et al 1991</a>]. As many as 95% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals eventually experience recurrent epistaxis, with one third having onset by age ten years, approximately 80% by age 20 years, and 90% before age 30 years [<a class="bk_pop" href="#hht.REF.berg.2003.585">Berg et al 2003</a>]. However, many do not have nosebleeds that are frequent or severe enough to cause anemia or to result in medical treatment or consultation. Epistaxis was a common cause of death in HHT before the development of blood transfusion.</p><p><b>Telangiectases</b> associated with HHT are found primarily on the lips, tongue, buccal mucosa, face, chest, and fingers. The average age of onset is generally later than epistaxis, but may be during childhood; 30% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals report telangiectases first appearing before age 20 years and two thirds before age 40 years [<a class="bk_pop" href="#hht.REF.berg.2003.585">Berg et al 2003</a>]. They may appear as pinhead-size lesions or as larger, even raised lesions with multiple draining venules. Telangiectases are distinguished from petechiae and angiomata by their ability to blanch with gentle pressure, and then immediately but often slowly refill. Because of their thin walls, narrow tortuous paths, and proximity to the surface of the skin or to a mucous membrane, telangiectases can rupture and bleed after only slight trauma. Since the contractile elements in the vessel wall are lacking, given the abnormal arterial connection, bleeding from telangiectases is frequently brisk and difficult to stop. Telangiectases of the skin are significantly less likely to bleed than those of the nasal mucosa.</p><p>Telangiectases are common in adulthood throughout the gastrointestinal (GI) mucosa, but most commonly, the stomach and the proximal small intestine (duodenum) are involved. Approximately one quarter of all individuals with HHT eventually have bleeding from GI telangiectases. It most commonly begins after age 50 years, and is slow but persistent; but can become increasingly severe with age [<a class="bk_pop" href="#hht.REF.plauchu.1989.291">Plauchu et al 1989</a>, <a class="bk_pop" href="#hht.REF.kjeldsen.2000.415">Kjeldsen &#x00026; Kjeldsen 2000</a>]. It presents more often as iron deficiency anemia than acute GI hemorrhage; but GI bleeding is a less common cause of iron deficiency in individuals with HHT than under-recognized epistaxis. No particular foods, activities, or medications have been identified as contributors to GI bleeding in individuals with HHT.</p><p><b>AVMs.</b> AVMs occur most commonly in the lungs, liver, and brain. Although hemorrhage is often the presenting symptom of cerebral AVMs, most visceral AVMs present as a consequence of blood shunting through the abnormal vessel and bypassing the capillary bed.</p><p>Pulmonary AVMs occur in approximately 30%-50% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#hht.REF.mcdonald.2011a.607">McDonald et al 2011a</a>] and can develop over time but rarely after age 30. Shunting of air, thrombi, and bacteria through pulmonary AVMs (thus bypassing the filtering capabilities of the lungs) may cause transient ischemic attacks (TIAs), embolic stroke, and cerebral and other abscesses. In one series, serious neurologic events including TIA, stroke, and brain abscess occurred in 30%-40% of individuals with pulmonary AVMs with feeding arteries 3.0 mm or greater in diameter [<a class="bk_pop" href="#hht.REF.white.1996.2627">White 1996</a>]. These neurologic complications may occur in individuals with <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> pulmonary AVMs and near-normal arterial oxygen tension. Pulmonary AVMs frequently enlarge with time [<a class="bk_pop" href="#hht.REF.white.1996.2627">White 1996</a>]. One study of 42 children with pulmonary AVMs demonstrated that children can have life-threatening complications from these lesions. More than half presented with exercise intolerance, cyanosis, or clubbing, and although the neurologic complications were less frequent than in adults, they had occurred in 19% prior to detection and treatment [<a class="bk_pop" href="#hht.REF.faughnan.2004.826">Faughnan et al 2004</a>]. Migraine headache and polycythemia are additional complications of pulmonary AVMs. Occasionally, a pulmonary AVM can rupture, leading to hemoptysis.</p><p>The frequency of hepatic vascular abnormalities was 74% in one study that systematically imaged the liver of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals using CT [<a class="bk_pop" href="#hht.REF.ianora.2004.250">Ianora et al 2004</a>] and 41% in another study using ultrasound examination [<a class="bk_pop" href="#hht.REF.buscarini.2004a.348">Buscarini et al 2004a</a>]. However, only a small minority (8% in the study using CT) were symptomatic. Hepatic AVMs can present as high-output heart failure, portal hypertension, or biliary disease [<a class="bk_pop" href="#hht.REF.garciatsao.2000.931">Garcia-Tsao et al 2000</a>]. Hepatic focal nodular hyperplasia is also associated with the shunting effects of blood through these high-flow vascular lesions [<a class="bk_pop" href="#hht.REF.buscarini.2004b.1089">Buscarini et al 2004b</a>, <a class="bk_pop" href="#hht.REF.brenard.2010.1253">Brenard et al 2010</a>].</p><p>In the brain, AVMs are typically present at birth. Cerebral AVMs occur in approximately 10% of individuals with HHT [<a class="bk_pop" href="#hht.REF.mcdonald.2011a.607">McDonald et al 2011a</a>].</p><p>Spinal AVMs appear to be significantly less common, but may present with paralysis.</p><p>Vascular lesions in the pancreas are common but rarely a clinical issue [<a class="bk_pop" href="#hht.REF.lacout.2010.479">Lacout et al 2010</a>].</p><p><b>Anemia.</b> Epistaxis, or less commonly GI bleeding, can cause mild to severe anemia, often requiring iron replacement therapy or rarely, blood transfusion. In middle age adults, GI bleeding becomes a more important contributor to anemia and iron deficiency.</p><p><b>Pulmonary hypertension</b> is another pulmonary vascular manifestation of HHT. Although much less common than pulmonary AVMs, it can either result from systemic arteriovenous shunting in the liver increasing cardiac output or be clinically and histologically indistinguishable from <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> pulmonary arterial hypertension [<a class="bk_pop" href="#hht.REF.cottin.2007.361">Cottin et al 2007</a>, <a class="bk_pop" href="#hht.REF.girerd.2010.851">Girerd et al 2010</a>, <a class="bk_pop" href="#hht.REF.austin.2013">Austin et al 2013</a>] (see <a href="/books/n/gene/pph/">Pulmonary Arterial Hypertension</a>).</p></div><div id="hht.Phenotype_Correlations_by_Gene"><h3>Phenotype Correlations by Gene</h3><p>Pulmonary AVMs are more common in individuals with <i>ENG</i> pathogenic variants, and hepatic AVMs are more common in individuals with <i>ACVRL1</i> pathogenic variants. However, both types are clearly multisystem vascular dysplasias with most manifestations described in both [<a class="bk_pop" href="#hht.REF.kjeldsen.2005.349">Kjeldsen et al 2005</a>, <a class="bk_pop" href="#hht.REF.bayraktoydemir.2006b.463">Bayrak-Toydemir et al 2006b</a>, <a class="bk_pop" href="#hht.REF.letteboer.2006.371">Letteboer et al 2006</a>, <a class="bk_pop" href="#hht.REF.lesca.2007.14">Lesca et al 2007</a>].</p><p>Pulmonary hypertension in the absence of severe vascular shunting, a rare HHT manifestation, has occurred most commonly in individuals with pathogenic variants in <i>ACVRL1,</i> but has also been reported in individuals with pathogenic variants in <i>ENG</i> [<a class="bk_pop" href="#hht.REF.soubrier.2013.d13">Soubrier et al 2013</a>].</p><p>Pathogenic variants in <i>SMAD4</i> have been reported in families with a combined syndrome of JPS and HHT [<a class="bk_pop" href="#hht.REF.gallione.2004.852">Gallione et al 2004</a>], as well as in families reported to have <a href="/books/n/gene/jps/">JPS</a> or HHT only. A recent study found that the majority of families with an <i>SMAD4</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> who had presented as JP only were found to have features of HHT when specifically reexamined for such manifestations [<a class="bk_pop" href="#hht.REF.omalley.2012.886">O'Malley et al 2012</a>].</p></div><div id="hht.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Data suggest that no absolute <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> exist between clinical phenotypes and specific pathogenic variants [<a class="bk_pop" href="#hht.REF.mcdonald.2015.1">McDonald et al 2015</a>].</p></div><div id="hht.Penetrance"><h3>Penetrance</h3><p>HHT displays age-related <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> with increased manifestations developing over a lifetime.</p><ul><li class="half_rhythm"><div>Approximately 50% of diagnosed individuals report having nosebleeds by age ten years and 80%-90% by age 21 years. As many as 95% eventually develop recurrent epistaxis.</div></li><li class="half_rhythm"><div>The percentage of individuals with telangiectases of the hands, face, and oral cavity is similar to the percentage with epistaxis, but the age of onset of telangiectases is generally five to 30 years later than for epistaxis [<a class="bk_pop" href="#hht.REF.plauchu.1989.291">Plauchu et al 1989</a>, <a class="bk_pop" href="#hht.REF.porteous.1992.527">Porteous et al 1992</a>].</div></li><li class="half_rhythm"><div>Cerebral AVMs are almost always <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> [<a class="bk_pop" href="#hht.REF.faughnan.2011.73">Faughnan et al 2011</a>]. Intracranial hemorrhage secondary to AVM can be the presenting symptom of HHT in infants and children with HHT [<a class="bk_pop" href="#hht.REF.morgan.2002.e12">Morgan et al 2002</a>].</div></li></ul></div><div id="hht.Anticipation"><h3>Anticipation</h3><p>While <a class="def" href="/books/n/gene/glossary/def-item/intrafamilial-variability/">intrafamilial variability</a> is considerable, there has been no systematic generational progression to suggest <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a>.</p></div><div id="hht.Nomenclature"><h3>Nomenclature</h3><p>The original description of the syndrome was made by Sutton in 1864. However, Osler in the USA, Parkes Weber in the UK, and Rendu in France are typically given credit; hence the eponymous Osler-Weber-Rendu syndrome (or Rendu-Osler-Weber in articles in the French literature). The designation "hereditary hemorrhagic telangiectasia" was suggested in 1912 by one of Osler's residents.</p><p>The <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> now identified as <i>ACVRL1</i> is referred to in many publications as <i>ALK1</i>. Note: Other genes were also previously named <i>ALK1</i>.</p></div><div id="hht.Prevalence"><h3>Prevalence</h3><p>A number of studies indicate that HHT is significantly more frequent than formerly thought, at least in the populations investigated. The overall incidence of HHT in North America is estimated at 1:10,000 [<a class="bk_pop" href="#hht.REF.marchuk.1998.269">Marchuk et al 1998</a>]; however, this is likely an underestimate [<a class="bk_pop" href="#hht.REF.guttmacher.2013">Guttmacher et al 2013</a>]. For example, when a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is diagnosed, it is not unusual to identify multiple relatives in the family who have not been diagnosed with HHT but have experienced epistaxis, embolic stroke, or GI bleeding.</p><p>HHT occurs with wide ethnic and geographic distribution. The condition is especially prevalent in the Netherland Antilles because of a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a>.</p></div></div><div id="hht.Genetically_Related_Allelic_Disorder"><h2 id="_hht_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p><b><i>ACVRL1</i>.</b> Pathogenic variants in <i>ACVRL1</i> are a rare cause of pulmonary arterial hypertension [<a class="bk_pop" href="#hht.REF.austin.2013">Austin et al 2013</a>].</p><p><b><i>ENG</i>.</b> No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>ENG</i>.</p><p><b><i>GDF2</i>.</b> No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>GDF2</i>.</p><p><b><i>SMAD4</i>.</b> Pathogenic variants in <i>SMAD4</i> have been reported in families with a combined syndrome of <a href="/books/n/gene/jps/">juvenile polyposis syndrome</a> (JPS) and HHT [<a class="bk_pop" href="#hht.REF.gallione.2004.852">Gallione et al 2004</a>], as well as in families who presented with JPS or HHT only [<a class="bk_pop" href="#hht.REF.howe.2004.484">Howe et al 2004</a>, <a class="bk_pop" href="#hht.REF.gallione.2006.793">Gallione et al 2006</a>, <a class="bk_pop" href="#hht.REF.prigoda.2006.722">Prigoda et al 2006</a>, <a class="bk_pop" href="#hht.REF.gallione.2010.333">Gallione et al 2010</a>]. One study found <i>SMAD4</i> pathogenic variants in three of 30 persons referred for DNA-based testing for HHT in whom a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ACVRL1</i> or <i>ENG</i> had not been identified [<a class="bk_pop" href="#hht.REF.gallione.2006.793">Gallione et al 2006</a>]. Another study showed that 2% of 194 persons referred for DNA-based testing for HHT had <i>SMAD4</i> pathogenic variants [<a class="bk_pop" href="#hht.REF.prigoda.2006.722">Prigoda et al 2006</a>]. Although the proportion of individuals with a pathogenic variant in <i>SMAD4</i> who manifest HHT only is unknown, it is suspected that all pathogenic variants in <i>SMAD4</i> put individuals and families at risk for manifestations of both JPS and HHT [<a class="bk_pop" href="#hht.REF.gallione.2010.333">Gallione et al 2010</a>]. Reports to date suggesting that the majority of individuals with <i>SMAD4</i> pathogenic variants have only JPS are likely attributable to <a class="def" href="/books/n/gene/glossary/def-item/variable-expressivity/">variable expressivity</a>, age-related <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of HHT, and clinical evaluation that did not focus on manifestations of HHT [<a class="bk_pop" href="#hht.REF.omalley.2012.886">O'Malley et al 2012</a>]</p></div><div id="hht.Differential_Diagnosis"><h2 id="_hht_Differential_Diagnosis_">Differential Diagnosis</h2><p>Telangiectases and epistaxis can be seen in otherwise healthy individuals.</p><p><b>Recurrent epistaxis</b> can be a sign of various bleeding diatheses, including <a href="/books/n/gene/von-willebrand/">von Willebrand disease</a>.</p><p><b>Telangiectases</b> occur in a number of conditions:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/ataxia-telangiectas/">Ataxia-telangiectasia</a>, characterized by progressive cerebellar ataxia beginning between age one and four years, oculomotor apraxia, frequent infections, choreoathetosis, telangiectases of the conjunctivae, immunodeficiency, and an increased risk for malignancy, particularly leukemia and lymphoma. Diagnosis relies on clinical findings (including slurred speech, truncal ataxia, and oculomotor apraxia), family history, and neuroimaging. Pathogenic variants in <i>ATM</i> are causative; inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li><li class="half_rhythm"><div>CRST (<i>c</i>alcinosis, <i>R</i>aynaud phenomenon, <i>s</i>clerodactyly, <i>t</i>elangiectasia) syndrome (OMIM <a href="http://omim.org/entry/181750" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">181750</a>)</div></li><li class="half_rhythm"><div><a href="/books/n/gene/rasa1-rel-dis/">Capillary malformation-arteriovenous malformation</a> (CM-AVM) caused in some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals by pathogenic variants in <i>RASA1. RASA1</i>-related disorders are characterized by the presence of multiple, small (1-2 cm in diameter) capillary malformations mostly localized on the face and limbs. About 30% of affected individuals also have associated arteriovenous malformations (AVMs) and/or arteriovenous fistulas (AFVs), fast-flow vascular anomalies that typically arise in the skin, muscle, bone, spine, and brain. In persons with <i>RASA1</i>-related disorders cutaneous zones of numerous pinpoint telangiectases &#x02013; each surrounded by a white pale halo and typically distributed on the limbs or trunk &#x02013; have also been described [<a class="bk_pop" href="#hht.REF.revencu.2013a.1632">Revencu et al 2013a</a>]. This distribution of telangiectases and the presence of "halos" surrounding each red spot is not typical of HHT. Several individuals with a <i>RASA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have the clinical diagnosis of Parkes Weber syndrome (multiple micro-AVFs associated with a cutaneous capillary stain and excessive soft tissue and skeletal growth of an affected limb).</div></li><li class="half_rhythm"><div>Hereditary benign telangiectasia (OMIM <a href="http://omim.org/entry/187260" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">187260</a>), characterized by widespread telangiectases, predominantly on the face, upper limbs, and upper trunk. The telangiectases are venular and associated with upper dermal atrophy. It should be suspected in persons without a history/family history of nosebleed or other bleeding, mucosal telangiectases, AVM, or characteristic pattern of telangiectasia distribution found in HHT.</div></li><li class="half_rhythm"><div>Pregnancy</div></li><li class="half_rhythm"><div>Chronic liver disease (However, the telangiectases are almost always of the "spider" class and occur on the face and chest and around the umbilicus.)</div></li></ul><p>Additionally, adults can develop one or a couple of cutaneous telangiectases with age. These often raise concern, especially when the person also has multiple cherry angiomata, which are quite frequent in older individuals and are unrelated to HHT.</p><p><b>Pulmonary AVMs.</b> Most individuals with a pulmonary AVM have HHT; an unknown percentage of individuals who have an <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> pulmonary AVM do not have HHT.</p><p><b>Cerebral AVMs</b> occur most frequently as an <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> finding, but may be a manifestation of HHT or another dominantly inherited vascular dysplasia such as <a href="/books/n/gene/rasa1-rel-dis/">capillary malformation-arteriovenous malformation</a> (CM-AVM) caused by pathogenic variants in <i>RASA1</i> [<a class="bk_pop" href="#hht.REF.eerola.2003.1240">Eerola et al 2003</a>, <a class="bk_pop" href="#hht.REF.revencu.b">Revencu et al 2013b</a>]. Families have also been reported with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> AVMs of the brain and no other features of HHT. However, the presence of multiple cerebral AVMs is highly suggestive of HHT [<a class="bk_pop" href="#hht.REF.bharatha.2012.72">Bharatha et al 2012</a>]. The absence of a family history of recurrent nosebleed and presence of telangiectases specifically on the lips, face, and hands best distinguish other vascular dysplasias from HHT.</p></div><div id="hht.Management"><h2 id="_hht_Management_">Management</h2><div id="hht.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with hereditary hemorrhagic telangiectasia (HHT), the following evaluations are recommended [<a class="bk_pop" href="#hht.REF.faughnan.2011.73">Faughnan et al 2011</a>, <a class="bk_pop" href="#hht.REF.mcdonald.2011a.607">McDonald et al 2011a</a>]:</p><ul><li class="half_rhythm"><div class="half_rhythm">Medical history, with particular attention to epistaxis and other bleeding, anemia or polycythemia, diseases of the heart, lung and liver, and neurologic symptoms</div></li><li class="half_rhythm"><div class="half_rhythm">Physical examination including inspection for telangiectases (particularly on fingers, lips, tongue, oropharynx, cheeks, or conjunctiva) and listening for abdominal bruits</div></li><li class="half_rhythm"><div class="half_rhythm">Complete blood count, with particular attention to anemia or polycythemia. If anemia is present, it is important to consider other causes of anemia, particularly when the anemia appears to be disproportionate to the amount of epistaxis. People with HHT may develop medical problems unrelated to HHT (e.g., ulcers or colon cancer) that can cause GI blood loss. Polycythemia raises suspicion for pulmonary arteriovenous malformations.</div></li><li class="half_rhythm"><div class="half_rhythm">Contrast echocardiography for detection of pulmonary shunting/AVM and measurement of the pulmonary artery systolic pressure as a screen for pulmonary artery hypertension. When pulmonary shunting is suggested (or if dependable contrast echocardiography is not available), CT angiography with cuts of 3 mm or less to define size and location of lesions(s) is the next step.</div></li><li class="half_rhythm"><div class="half_rhythm">Head MRI (with and without gadolinium) to detect cerebral AVMs, performed as early as possible, preferably in the first year of life. Adults, including those screened with MRI in infancy, should all have a screening head MRI to detect unsuspected vascular lesions and occult cerebral abscesses.</div></li><li class="half_rhythm"><div class="half_rhythm">Consideration of ultrasound or CT examination for evidence of hepatic AVM if the individual has symptoms such as high-output failure associated with hepatic vascular abnormalities or otherwise unexplained elevations in liver function tests, or if presence of a visceral AVM would confirm a diagnosis of HHT</div><div class="half_rhythm">Note: Screening for hepatic AVMs in asymptomatic individuals is not common practice because:</div><ul><li class="half_rhythm"><div>Hepatic AVMs are not usually symptomatic and, when they do become symptomatic, it is not sudden and catastrophic, as is seen with pulmonary AVMs and cerebral AVMs; and</div></li><li class="half_rhythm"><div>Treatment options for hepatic AVMs are less satisfactory than those for pulmonary or cerebral AVMs.</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="hht.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="hht.Nosebleeds"><h4>Nosebleeds</h4><p>It is appropriate to consider intervention for nosebleeds in the case of anemia attributable to the nosebleeds or if an individual feels that the frequency or duration interferes significantly with normal activities.</p><p>Humidification and the daily application of nasal lubricants may be helpful.</p><p>Hemostatic products (gauze, sponge or powder products) available over the counter help individuals self-manage significant nosebleeds.</p><p>Laser ablation typically done under general anesthesia may be the most effective intervention for control of mild to moderate nosebleeds. Office-based sclerotherapy was shown to be a potentially safe and useful alternative in an uncontrolled Spanish study [<a class="bk_pop" href="#hht.REF.morais.2012.80">Morais et al 2012</a>] and a small retrospective US pilot study [<a class="bk_pop" href="#hht.REF.boyer.2011.319">Boyer et al 2011</a>].</p><p>Young's nasal closure is a consideration for severe epistaxis which has proven unresponsive to the above methods [<a class="bk_pop" href="#hht.REF.richer.2012.401">Richer et al 2012</a>]. Surgical treatment for severe epistaxis in persons with HHT should be performed by surgeons who treat people with HHT regularly.</p><p>Oral drug therapy. A meta-analysis of studies of hormonal and anti-hormonal treatment concluded that estrogen-progesterone at doses used for oral contraception may eliminate bleeding in symptomatic HHT and is a reasonable initial option to consider for fertile women [<a class="bk_pop" href="#hht.REF.jameson.2004.705">Jameson &#x00026; Cave 2004</a>]. An anti-estrogen, tamoxifen, was reported to decrease nosebleeds in one series [<a class="bk_pop" href="#hht.REF.yaniv.2009.284">Yaniv et al 2009</a>]. Antifibrinolytic drugs such as tranexamic acid (Cyklokapron<sup>&#x000ae;</sup>) have been used with some success in selected individuals; the associated risks are not well established [<a class="bk_pop" href="#hht.REF.fernandezl.2007.254">Fernandez-L et al 2007</a>]. Thalidomide, an angiogenesis inhibitor, reduced the severity and frequency of nosebleeds in six of seven <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in a small series [<a class="bk_pop" href="#hht.REF.lebrin.2010.420">Lebrin et al 2010</a>]. Oral propranolol has also been suggested as a potential treatment [<a class="bk_pop" href="#hht.REF.albi_ana.2012.41">Albi&#x000f1;ana et al 2012</a>].</p><p>Topical drug therapy. Current evidence and experience suggest that the simple humidification and moisturizing effects of medicated sprays and ointments are more helpful than the particular medication. A multi-HHT center randomized, cross-over, placebo controlled trial (NOSE Trial) to study the efficacy of several medicated nose sprays (bevacizumab, estriol, and tranexamic acid) in the treatment of epistaxis concluded that all groups, including the placebo group using saline spray, had a significant improvement in epistaxis. None of the three topical therapies was any better at decreasing epistaxis frequency than twice-daily saline spray [<a class="bk_pop" href="#hht.REF.whitehead.2016.943">Whitehead et al 2016</a>]. Another randomized, multicenter, placebo-controlled clinical trial of three doses of bevacizumab nasal spray was published simultaneously with the NOSE Trial. Here again, topical bevacizumab had no effect on epistaxis [<a class="bk_pop" href="#hht.REF.dupuisgirod.2016.934">Dupuis-Girod et al 2016</a>]. Case reports or small series suggest that these and other topically administered agents (e.g., timolol 0.5% ophthalmic solution) may help reduce the duration or frequency of nosebleeds in those with HHT [<a class="bk_pop" href="#hht.REF.flanagan.2012.69">Flanagan et al 2012</a>, <a class="bk_pop" href="#hht.REF.guldmann.2012.953">Guldmann et al 2012</a>, <a class="bk_pop" href="#hht.REF.olitsky.2012.375">Olitsky 2012</a>, <a class="bk_pop" href="#hht.REF.reh.2013.820">Reh et al 2013</a>].</p><p>Case reports and a small series [<a class="bk_pop" href="#hht.REF.bose.2009.2143">Bose et al 2009</a>, <a class="bk_pop" href="#hht.REF.brinkerhoff.2011.688">Brinkerhoff et al 2011</a>, <a class="bk_pop" href="#hht.REF.suppressa.2011.365">Suppressa et al 2011</a>, <a class="bk_pop" href="#hht.REF.dupuisgirod.2012.948">Dupuis-Girod et al 2012</a>, <a class="bk_pop" href="#hht.REF.thompson.2014.91">Thompson et al 2014</a>] suggest that IV administration of the anti-angiogenic drug bevacizumab may be efficacious in those with severe, intractable nosebleeds.</p></div><div id="hht.Gastrointestinal_Bleeding"><h4>Gastrointestinal Bleeding</h4><p>Treatment is unnecessary unless aggressive iron therapy has been ineffective in maintaining hemoglobin concentration in the normal range.</p><p>Endoscopy, capsule endoscopy, mesenteric and celiac angiography, and radionuclide studies may be used to localize the source of bleeding and its type [<a class="bk_pop" href="#hht.REF.gr_ve.2010.760">Gr&#x000e8;ve et al 2010</a>].</p><p>Endoscopic application of a heater probe, bicap, or laser is the mainstay of local treatment.</p><p>Small bowel bleeding sites and larger vascular malformations can be removed surgically after they are identified by nuclear medicine studies.</p><p>For severe GI bleeding associated with intractable iron deficiency anemia, various pharmacologic agents have shown promise based on case reports or small uncontrolled series. Treatment with oral estrogen-progesterone or tranexamic acid has decreased transfusion needs [<a class="bk_pop" href="#hht.REF.proctor.2008.756">Proctor et al 2008</a>]. A number of single cases of dramatic reduction in GI bleeding after IV administration of the anti-angiogenic drug bevacizumab have been reported [<a class="bk_pop" href="#hht.REF.flieger.2006.631">Flieger et al 2006</a>, <a class="bk_pop" href="#hht.REF.fodstad.2011.611">Fodstad et al 2011</a>].</p></div><div id="hht.Anemia"><h4>Anemia</h4><p>Treatment of anemia with iron replacement and red blood cell transfusion, if necessary, is appropriate.</p><p>Persons with iron deficiency who are intolerant of or do not respond to oral iron benefit from parenteral administration of iron.</p></div><div id="hht.Pulmonary_AVMs"><h4>Pulmonary AVMs</h4><p>Treatment of pulmonary AVMs is indicated for dyspnea, exercise intolerance, and hypoxemia, but is most important for prevention of lung hemorrhage and the neurologic complications of brain abscess and stroke, even in those who are asymptomatic with respect to pulmonary function and oxygen saturation. Any pulmonary AVM with a feeding vessel that exceeds 1.0 mm in diameter requires consideration of occlusion [<a class="bk_pop" href="#hht.REF.trerotola.2010.837">Trerotola &#x00026; Pyeritz 2010</a>]. Transcatheter embolotherapy (TCE) with coils, occluder devices (Amplatzer<sup>&#x000ae;</sup>), or both is the treatment of choice. Occasionally, a small lesion cannot be reached because of its location or the size of the feeding vessel. Multiple coils may be needed to occlude AVMs with large or multiple feeding arteries.</p><p>Long-term follow up by chest CT and/or contrast echocardiography is indicated after transcatheter occlusion of pulmonary AVMs because of reported recanalization and development or growth of untreated pulmonary AVMs [<a class="bk_pop" href="#hht.REF.cottin.2007.361">Cottin et al 2007</a>]. Usually a follow-up CT is done six to 12 months post-occlusion, and if no recanalized or new PAVMs are noted, follow-up CT is done at five-year intervals thereafter [<a class="bk_pop" href="#hht.REF.trerotola.2010.837">Trerotola &#x00026; Pyeritz 2010</a>, <a class="bk_pop" href="#hht.REF.faughnan.2011.73">Faughnan et al 2011</a>].</p></div><div id="hht.Hepatic_AVMs"><h4>Hepatic AVMs</h4><p>Treatment of cardiac failure or liver failure secondary to hepatic AVMs is currently problematic. Embolization of hepatic AVMs, which is successful for treatment of pulmonary AVMs, has led to lethal hepatic infarctions. Most individuals with symptomatic hepatic AVMs can be satisfactorily managed with intensive medical therapy [<a class="bk_pop" href="#hht.REF.buscarini.2011.2166">Buscarini et al 2011</a>].</p><p>Liver transplantation has been the standard treatment for those (usually older) individuals whose symptoms of hepatic failure do not respond to medical management [<a class="bk_pop" href="#hht.REF.buscarini.2006.1040">Buscarini et al 2006</a>, <a class="bk_pop" href="#hht.REF.lerut.2006.854">Lerut et al 2006</a>, <a class="bk_pop" href="#hht.REF.dupuisgirod.2010.340">Dupuis-Girod et al 2010</a>, <a class="bk_pop" href="#hht.REF.lee.2010.3059">Lee et al 2010</a>, <a class="bk_pop" href="#hht.REF.chavan.2013.106">Chavan et al 2013</a>].</p><p>Bevacizumab administered intravenously has been reported to decrease cardiac output and symptoms of heart failure in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with severe symptoms secondary to hepatic AVMs in case reports and one series [<a class="bk_pop" href="#hht.REF.mitchell.2008.210">Mitchell et al 2008</a>, <a class="bk_pop" href="#hht.REF.dupuisgirod.2012.948">Dupuis-Girod et al 2012</a>].</p><p>Liver biopsy should be avoided in individuals with HHT [<a class="bk_pop" href="#hht.REF.buscarini.2006.1040">Buscarini et al 2006</a>].</p></div><div id="hht.Cerebral_AVMs"><h4>Cerebral AVMs</h4><p>Cerebral AVMs greater than 1.0 cm in diameter are usually treated using neurovascular surgery, embolotherapy, and/or stereotactic radiosurgery.</p><p>Note: Before proceeding with treatment for any visceral AVM, individuals and their doctors are encouraged to contact the nearest multidisciplinary HHT clinic, which can be located through the support group, <a href="http://curehht.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cure HHT</a>, to assure that appropriate diagnostic and treatment plans are in place.</p></div><div id="hht.Intestinal_Polyps"><h4>Intestinal Polyps</h4><p>Any individual diagnosed with juvenile polyposis (JP) should be screened for manifestations of HHT, and the family should be screened for polyps. Any person with HHT who has gastrointestinal polyps, especially at an early age, should be evaluated for JP and managed accordingly (see <a href="/books/n/gene/jps/">Juvenile Polyposis Syndrome</a>).</p></div></div><div id="hht.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>See <a href="#hht.Treatment_of_Manifestations">Treatment of Manifestations</a>. Prevention is currently focused at ablating, occluding, resecting or shrinking telangiectases and AVMs to prevent associated morbidity and mortality.</p></div><div id="hht.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>If contrast echocardiography is positive for pulmonary shunting, even if no pulmonary AVM is demonstrated by chest CT, a lifetime recommendation for prophylactic antibiotics in accordance with the American Heart Association protocol for dental cleaning and other "dirty" procedures is advised because of the risk of abscess, particularly brain abscess, associated with right to left shunting [<a class="bk_pop" href="#hht.REF.dupuisgirod.2007.841">Dupuis-Girod et al 2007</a>]. For the same reason, an air filter or extreme caution not to introduce air bubbles is recommended with IV lines.</p><p>Note: The risk associated with these lesions is not for subacute bacterial endocarditis (SBE).</p></div><div id="hht.Surveillance"><h3>Surveillance</h3><p>The following protocol is recommended for follow up of all individuals for whom the diagnosis of HHT is definite and for all individuals at risk for HHT based on family history in whom HHT has not been ruled out by molecular diagnosis [<a class="bk_pop" href="#hht.REF.faughnan.2011.73">Faughnan et al 2011</a>]:</p><ul><li class="half_rhythm"><div>Annual evaluation by a health care provider familiar with HHT, including interval history for epistaxis or other bleeding, shortness of breath or decreased exercise tolerance, and headache or other neurologic symptoms</div></li><li class="half_rhythm"><div>Periodic hematocrit/hemoglobin and ferritin determination with appropriate treatment for iron deficiency anemia</div></li><li class="half_rhythm"><div>Reevaluation for pulmonary AVM at approximately five-year intervals [<a class="bk_pop" href="#hht.REF.nawaz.2008.1582">Nawaz et al 2008</a>]:</div><ul><li class="half_rhythm"><div>Contrast echocardiogram is used (if available) if the previous contrast echocardiogram did not reveal evidence of a pulmonary or intracardiac right to left shunt.</div></li><li class="half_rhythm"><div>Chest CT with contrast rather than pulmonary angiography is used if the previous contrast echocardiogram revealed evidence of a right to left shunt.</div></li></ul></li><li class="half_rhythm"><div>Reevaluation for cerebral AVM. While cerebral AVMs are nearly always <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a>, development or evolution of cerebral AVMs in the first two decades of life has been reported [<a class="bk_pop" href="#hht.REF.hetts.2014.1376">Hetts et al 2014</a>]. Accordingly, many HHT experts recommend rescreening the brain once more after puberty if the initial brain MRI was done in childhood.</div></li><li class="half_rhythm"><div>Periodic screening for gastrointestinal polyps and malignant change in persons with juvenile polyps</div></li></ul><p><b>Childhood</b></p><ul><li class="half_rhythm"><div>Because serious complications of pulmonary and cerebral AVM can occur at any age [<a class="bk_pop" href="#hht.REF.meizahav.2006.596">Mei-Zahav et al 2006</a>, <a class="bk_pop" href="#hht.REF.curie.2007.299">Curie et al 2007</a>], screening for pulmonary and cerebral AVMs is recommended in children from families with HHT, especially those with <i>ENG</i> pathogenic variants [<a class="bk_pop" href="#hht.REF.alsaleh.2009.875">Al-Saleh et al 2009</a>].</div></li><li class="half_rhythm"><div>Head MRI with and without gadolinium is recommended as early as the first few months of life [<a class="bk_pop" href="#hht.REF.faughnan.2011.73">Faughnan et al 2011</a>].</div></li><li class="half_rhythm"><div>Pulse oximetry in the supine and sitting positions every one to two years during childhood is recommended as a minimum to screen for pulmonary AVMs. It may be of concern if the sitting value is even a few percentage points below that of the supine value. (Since most pulmonary AVMs are in the lower lobes, many individuals with pulmonary AVMs have higher oxygen saturation when lying than when sitting because of the effect of gravity.) Oxygen saturations below 97% should be followed up with contrast echocardiography. Many, but not all, serious complications of pulmonary AVM during childhood have occurred in hypoxemic children.</div></li><li class="half_rhythm"><div>By at least age ten years, additional evaluation should be performed by contrast echocardiography, with a follow-up CT if positive.</div></li></ul></div><div id="hht.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Individuals with significant epistaxis are advised to avoid vigorous nose blowing, lifting of heavy objects, straining during bowel movements, and finger manipulation in the nose. Some individuals with HHT experience increased epistaxis after drinking alcohol.</p><p>Most otolaryngologists with experience treating individuals with HHT advise against electric and chemical cautery and transcatheter embolotherapy for treatment of recurrent nosebleeds in most situations.</p><p>Anticoagulants including aspirin and nonsteroidal anti-inflammatory agents such as ibuprofen that interfere with normal clotting should be avoided unless required for treatment of other medical conditions. In one study, lower dose agents, particularly anti-platelet agents, were not associated with hemorrhage in a high proportion of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. The findings support the use of antiplatelet or anticoagulant agents, with caution, if there is a very strong indication for their use [<a class="bk_pop" href="#hht.REF.devlin.2013.876">Devlin et al 2013</a>].</p><p>Scuba diving should be avoided unless contrast echocardiography performed within the last five years was negative for evidence of a right to left shunt.</p><p>Liver biopsy should be avoided in individuals with HHT [<a class="bk_pop" href="#hht.REF.buscarini.2006.1040">Buscarini et al 2006</a>].</p></div><div id="hht.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate at-risk relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who would benefit from preventive measures (see <a href="#hht.Prevention_of_Primary_Manifestations">Prevention of Primary Manifestations</a>) and prompt initiation of treatment to reduce morbidity and mortality.</p><p>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known, evaluate with <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p>If the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is not known and, consequently, HHT cannot been ruled out by molecular diagnosis, at-risk family members should follow the same protocol as is recommended for individuals in whom the diagnosis of HHT is definite (see <a href="#hht.Surveillance">Surveillance</a>).</p><ul><li class="half_rhythm"><div>Individuals older than age 40 years should have a targeted medical history and clinical examination for features of HHT. The absence of mild but recurrent epistaxis and subtle telangiectases in characteristic locations on careful examination is reassuring.</div></li><li class="half_rhythm"><div>In individuals age 40 years and younger, targeted medical history and clinical examination for features of HHT in addition to an evaluation for brain and pulmonary AVMs should be done initially, as features of HHT may not be identified by medical history and clinical examination in younger individuals.</div></li></ul><p>See <a href="#hht.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="hht.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Pregnant women with HHT and untreated pulmonary AVMs are also at high risk for lung hemorrhage and cerebral complications of air embolism. Women with treated pulmonary AVMs appear to be at no higher risk during pregnancy than those without pulmonary AVMs.</p></div><div id="hht.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Newer therapies designed to interfere with the development of abnormal vascular connections include thalidomide and bevacizumab; while numerous case reports and small uncontrolled series tout promise, controlled trials are needed [<a class="bk_pop" href="#hht.REF.flieger.2006.631">Flieger et al 2006</a>, <a class="bk_pop" href="#hht.REF.mitchell.2008.210">Mitchell et al 2008</a>, <a class="bk_pop" href="#hht.REF.bose.2009.2143">Bose et al 2009</a>, <a class="bk_pop" href="#hht.REF.davidson.2010.432">Davidson et al 2010</a>, <a class="bk_pop" href="#hht.REF.lebrin.2010.420">Lebrin et al 2010</a>, <a class="bk_pop" href="#hht.REF.brinkerhoff.2011.688">Brinkerhoff et al 2011</a>, <a class="bk_pop" href="#hht.REF.fodstad.2011.611">Fodstad et al 2011</a>, <a class="bk_pop" href="#hht.REF.suppressa.2011.365">Suppressa et al 2011</a>, <a class="bk_pop" href="#hht.REF.dupuisgirod.2012.948">Dupuis-Girod et al 2012</a>].</p><p>Search <a href="http://clinicaltrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="hht.Genetic_Counseling"><h2 id="_hht_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="hht.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Hereditary hemorrhagic telangiectasia (HHT) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="hht.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with HHT have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with HHT may rarely have the disorder as the result of <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> or <a class="def" href="/books/n/gene/glossary/def-item/somatic-pathogenic-variant/">somatic pathogenic variant</a> [<a class="bk_pop" href="#hht.REF.best.2011.358">Best et al 2011</a>].</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a child who represents an apparent <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) include physical examination, documentation of medical history targeted at symptoms and manifestations of HHT, and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ACVRL1</i>, <i>ENG</i>, <i>GDF2</i>, or <i>SMAD4</i> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Though theoretically possible, no instances of germline mosaicism have been reported.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>/has a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the variant is 50%.</div></li><li class="half_rhythm"><div>When the parents are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be lower. It should be noted, however, that although highly penetrant, the disease may not present until after age 40 years. Observable symptoms and manifestations can be subtle, even well into adulthood.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is presumed to be slightly greater than that of the general population (though still &#x0003c;1%) because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with HHT has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in an HHT-related <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, his or her family members are at risk.</p></div><div id="hht.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#hht.Surveillance">Surveillance</a> and <a href="#hht.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a></b>. When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>Testing of at-risk asymptomatic individuals.</b> Consideration of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of young, at-risk family members is appropriate for guiding medical management (see <a href="#hht.Surveillance">Surveillance</a>). Molecular genetic testing can be used with certainty to clarify the genetic status of at-risk family members when a clinically diagnosed relative has undergone molecular genetic testing and is found to have a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in an HHT-related <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p><p>Testing of asymptomatic at-risk family members usually involves pre-test consultation to discuss the possible impact of positive and negative test results. Those seeking testing should be counseled regarding possible problems that they may encounter with respect to health, life, and disability insurance coverage, employment and educational discrimination, and changes in social and family interaction. Informed consent should be procured and records kept confidential. Individuals identified to have a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of the four HHT-related genes need long-term follow up and evaluations. Although identifying <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> relatives when the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> pathogenic variant is known results in considerable savings of health care costs over the life of the at-risk relative, for a variety of reasons, individuals at 50% risk for inheriting HHT often decline <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> when the familial pathogenic variant is known [<a class="bk_pop" href="#hht.REF.bernhardt.2012.604">Bernhardt et al 2012</a>].</p><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a>, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="hht.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ACVRL1</i>, <i>ENG</i>, <i>GDF2</i>, or <i>SMAD4</i> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="hht.Resources"><h2 id="_hht_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Cure HHT</b></div><div>PO Box 329</div><div>Monkton MD 21111</div><div><b>Phone:</b> 410-357-9932</div><div><b>Fax:</b> 410-357-0655</div><div><b>Email:</b> hhtinfo@curehht.org</div><div><a href="http://curehht.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.curehht.org</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Hereditary%20Hemorrhagic%20Telangiectasia&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hereditary Hemorrhagic Telangiectasia</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=hereditaryhemorrhagictelangiectasia" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hereditary hemorrhagic telangiectasia</a></div></li></ul></div><div id="hht.Molecular_Genetics"><h2 id="_hht_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="hht.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Hereditary Hemorrhagic Telangiectasia: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1351/table/hht.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hht.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_hht.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_hht.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_hht.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_hht.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_hht.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_hht.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_hht.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/94" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ACVRL1</i></a></td><td headers="hd_b_hht.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=94" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">12q13<wbr style="display:inline-block"></wbr>​.13</a></td><td headers="hd_b_hht.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P37023" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Serine/threonine-protein kinase receptor R3</a></td><td headers="hd_b_hht.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://arup.utah.edu/database/ACVRL1/ACVRL1_welcome.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HHT Mutation Database (ACVRL1)</a><br /><a href="http://databases.lovd.nl/shared/genes/ACVRL1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ACVRL1 database</a></td><td headers="hd_b_hht.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ACVRL1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ACVRL1</a></td><td headers="hd_b_hht.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ACVRL1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ACVRL1</a></td></tr><tr><td headers="hd_b_hht.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2022" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ENG</i></a></td><td headers="hd_b_hht.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2022" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">9q34<wbr style="display:inline-block"></wbr>​.11</a></td><td headers="hd_b_hht.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P17813" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Endoglin</a></td><td headers="hd_b_hht.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://arup.utah.edu/database/ENG/ENG_display.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HHT Mutation Database (ENG)</a><br /><a href="http://databases.lovd.nl/shared/genes/ENG" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ENG database</a></td><td headers="hd_b_hht.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ENG" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ENG</a></td><td headers="hd_b_hht.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ENG[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ENG</a></td></tr><tr><td headers="hd_b_hht.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2658" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>GDF2</i></a></td><td headers="hd_b_hht.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2658" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">10q11<wbr style="display:inline-block"></wbr>​.22</a></td><td headers="hd_b_hht.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9UK05" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Growth/differentiation factor 2</a></td><td headers="hd_b_hht.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_hht.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GDF2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GDF2</a></td><td headers="hd_b_hht.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=GDF2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GDF2</a></td></tr><tr><td headers="hd_b_hht.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/4089" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SMAD4</i></a></td><td headers="hd_b_hht.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=4089" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">18q21<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_hht.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q13485" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Mothers against decapentaplegic homolog 4</a></td><td headers="hd_b_hht.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://arup.utah.edu/database/SMAD4/SMAD4_display.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMAD4 Database</a><br /><a href="http://databases.lovd.nl/shared/genes/SMAD4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMAD4 database</a></td><td headers="hd_b_hht.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SMAD4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMAD4</a></td><td headers="hd_b_hht.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SMAD4[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMAD4</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="hht.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="hht.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Hereditary Hemorrhagic Telangiectasia (<a href="/omim/131195,175050,187300,600376,600993,601101,601284,605120,610655,615506" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1351/table/hht.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hht.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/131195" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">131195</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ENDOGLIN; ENG</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/175050" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">175050</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME; JPHT</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/187300" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">187300</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 1; HHT1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600376" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600376</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 2; HHT2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600993" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600993</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 4; SMAD4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601101" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601101</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 3; HHT3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601284" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601284</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ACTIVIN A RECEPTOR, TYPE II-LIKE 1; ACVRL1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605120" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605120</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GROWTH/DIFFERENTIATION FACTOR 2; GDF2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/610655" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">610655</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 4; HHT4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/615506" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">615506</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 5; HHT5</td></tr></tbody></table></div></div><div id="hht.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p>Currently, all known genetic defects that cause HHT are in genes that encode proteins within the transforming growth factor beta (TGF-&#x003b2;) signaling pathway.</p><div id="hht.ACVRL1"><h4><i>ACVRL1</i></h4><p><b>Gene structure.</b>
<i>ACVRL1</i> contains ten exons and spans approximately 14 kb of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1351/#hht.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Current data suggest that most of pathogenic variants in <i>ACVRL1</i> are functionally <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> alleles [<a class="bk_pop" href="#hht.REF.berg.1997.60">Berg et al 1997</a>, <a class="bk_pop" href="#hht.REF.pece.1997.2568">Pece et al 1997</a>, <a class="bk_pop" href="#hht.REF.gallione.1998.286">Gallione et al 1998</a>, <a class="bk_pop" href="#hht.REF.richardsyutz.2010.61">Richards-Yutz et al 2010</a>]. No common pathogenic variants have been identified. The frequency of pathogenic variants is highest in exons 8, 7, and 3, but these account for only 65% of pathogenic variants identified and variants have been identified in all exons. Missense variants account for more than half (53%) of pathogenic variants detected; deletions, insertions, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants have also been reported [<a class="bk_pop" href="#hht.REF.abdalla.2006.97">Abdalla &#x00026; Letarte 2006</a>, <a class="bk_pop" href="#hht.REF.richardsyutz.2010.61">Richards-Yutz et al 2010</a>]. (For more information, see <a href="/books/NBK1351/#hht.molgen.TA">Table A</a>.)</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Serine/threonine-protein kinase receptor R3 is a type I cell-surface receptor for the TGF-superfamily of ligands. It is expressed predominantly on endothelial cells [<a class="bk_pop" href="#hht.REF.abdalla.2006.97">Abdalla &#x00026; Letarte 2006</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Current data suggest that most pathogenic variants in <i>ACVRL1</i> result in loss of protein expression. HHT is assumed to be the result of <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a> [<a class="bk_pop" href="#hht.REF.abdalla.2006.97">Abdalla &#x00026; Letarte 2006</a>].</p></div><div id="hht.ENG"><h4><i>ENG</i></h4><p><b>Gene structure.</b>
<i>ENG</i> contains 14 exons and spans approximately 40 kb of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1351/#hht.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Current data suggest that approximately two thirds of variants in <i>ENG</i> are functionally <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> alleles [<a class="bk_pop" href="#hht.REF.berg.1997.60">Berg et al 1997</a>, <a class="bk_pop" href="#hht.REF.pece.1997.2568">Pece et al 1997</a>, <a class="bk_pop" href="#hht.REF.gallione.1998.286">Gallione et al 1998</a>, <a class="bk_pop" href="#hht.REF.richardsyutz.2010.61">Richards-Yutz et al 2010</a>]. There are no common pathogenic variants. The total number of variants per <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> is similar with the exception of exons 1, 9b, 12, and 13, which have fewer variants. Pathogenic variants of all types have been reported [<a class="bk_pop" href="#hht.REF.abdalla.2006.97">Abdalla &#x00026; Letarte 2006</a>]. (For more information, see <a href="/books/NBK1351/#hht.molgen.TA">Table A</a>.)</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Endoglin is a component of the transforming growth factor beta (TGF-beta) receptor complex. It is expressed predominantly on endothelial cells.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Current data suggest that most pathogenic variants in <i>ENG</i> result in loss of protein expression. HHT is assumed to be the result of <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a> [<a class="bk_pop" href="#hht.REF.abdalla.2006.97">Abdalla &#x00026; Letarte 2006</a>].</p></div><div id="hht.GDF2"><h4><i>GDF2</i></h4><p><b>Gene structure.</b>
<i>GDF2</i> (also known as <i>BMP9</i>) is a small <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> comprising two exons and a transcript of 1955 bp (<a href="/nuccore/NM_016204.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_016204.2</a>). For a detailed summary of gene and protein information, see <a href="/books/NBK1351/#hht.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Missense variants in <i>GDF2</i> were identified in three individuals with features of HHT including epistaxis [<a class="bk_pop" href="#hht.REF.wooderchakdonahue.2013.530">Wooderchak-Donahue et al 2013</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>GDF2</i> encodes growth/differentiation factor 2 (also known as <i>BMP9</i> or bone morphogenetic protein 9), a protein of 429 amino acids (<a href="/protein/NP_057288.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_057288.1</a>). After post-translational cleavage of the signal peptide and the propeptide, the mature peptide is 110 amino acid residues. It is a member of the bone morphogenetic protein family and the TGF-beta superfamily. The members of this family are regulators of cell growth and differentiation in both embryonic and adult tissues.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Cell culture studies suggested that these variants resulted in loss of mature protein and/or function. A <i>bmp9</i>-deficient zebrafish model demonstrated that <i>BMP9</i> is involved in angiogenesis [<a class="bk_pop" href="#hht.REF.wooderchakdonahue.2013.530">Wooderchak-Donahue et al 2013</a>].</p></div><div id="hht.SMAD4"><h4><i>SMAD4</i></h4><p><b>Gene structure.</b>
<i>SMAD4</i> contains 11 exons and has a <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> of 2680 bp. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1351/#hht.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> There are no common pathogenic variants and all types of variants have been described. More than two thirds of pathogenic variants reported are functionally <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> alleles (see <a href="http://arup.utah.edu/database/SMAD4/SMAD4_display.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><i>SMAD4</i> Database</a>). Although <i>SMAD4</i> pathogenic variants in individuals with <a href="/books/n/gene/jps/">JP</a>-HHT have shown a tendency to cluster in the MH2 <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, pathogenic variants in other parts of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> also cause the combined syndrome. Any individual with an <i>SMAD4</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> should be considered at risk for manifestations of both JP and HHT [<a class="bk_pop" href="#hht.REF.gallione.2010.333">Gallione et al 2010</a>, <a class="bk_pop" href="#hht.REF.omalley.2012.886">O'Malley et al 2012</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>SMAD4</i> encodes a 552-amino acid protein that functions as an intracellular signaling molecule in the TGF-beta/BMP pathway.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Most pathogenic variants in <i>SMAD4</i> result in non-expressed proteins. HHT is assumed to be the result of <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a>.</p></div></div></div><div id="hht.References"><h2 id="_hht_References_">References</h2><div id="hht.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hht.REF.aassar.1991.977">Aassar OS, Friedman CM, White RI Jr. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">Laryngoscope. </span>1991;<span class="ref-vol">101</span>:977–80.</span> [<a href="/pubmed/1886446" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1886446</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.abdalla.2006.97">Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:97–110.</span> [<a href="/pmc/articles/PMC2603035/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2603035</span></a>] [<a href="/pubmed/15879500" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15879500</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.albi_ana.2012.41">Albi&#x000f1;ana V, Recio-Poveda L, Zarrabeitia R, Bernab&#x000e9;u C, Botella LM. Propranolol as antiangiogenic candidate for the therapy of hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">Thromb Haemost. </span>2012;<span class="ref-vol">108</span>:41–53.</span> [<a href="/pubmed/22552254" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22552254</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.alsaleh.2009.875">Al-Saleh S, Mei-Zahav M, Faughnan ME, MacLusky IB, Carpenter S, Letarte M, Ratjen F. Screening for pulmonary and cerebral arteriovenous malformations in children with hereditary haemorrhagic telangiectasia. <span><span class="ref-journal">Eur Respir J. </span>2009;<span class="ref-vol">34</span>:875–81.</span> [<a href="/pubmed/19386691" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19386691</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.austin.2013">Austin ED, Newman JH, Loyd JE, Phillips JA III. Heritable and idiopathic forms of pulmonary arterial hypertension. In: Rimoin DL, Pyeritz RE, Korf BR, eds. <em>Emery and Rimoin's Principles and Practice of Medical Genetics</em>. 6 ed. Chap 48. Academic Press; 2013.</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.bayraktoydemir.2006a.2155">Bayrak-Toydemir P, McDonald J, Akarsu N, Toydemir RM, Calderon F, Tuncali T, Tang W, Miller F, Mao R. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. <span><span class="ref-journal">Am J Med Genet A. </span>2006a;<span class="ref-vol">140</span>:2155–62.</span> [<a href="/pubmed/16969873" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16969873</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.bayraktoydemir.2006b.463">Bayrak-Toydemir P, McDonald J, Markewitz B, Lewin S, Miller F, Chou LS, Gedge F, Tang W, Coon H, Mao R. Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: mutations and manifestations. <span><span class="ref-journal">Am J Med Genet A. </span>2006b;<span class="ref-vol">140</span>:463–70.</span> [<a href="/pubmed/16470787" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16470787</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.berg.2003.585">Berg J, Porteous M, Reinhardt D, Gallione C, Holloway S, Umasunthar T, Lux A, McKinnon W, Marchuk D, Guttmacher A. Hereditary haemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK1 mutations. <span><span class="ref-journal">J Med Genet. </span>2003;<span class="ref-vol">40</span>:585–90.</span> [<a href="/pmc/articles/PMC1735540/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735540</span></a>] [<a href="/pubmed/12920067" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12920067</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.berg.1997.60">Berg JN, Gallione CJ, Stenzel TT, Johnson DW, Allen WP, Schwartz CE, Jackson CE, Porteous ME, Marchuk DA. The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. <span><span class="ref-journal">Am J Hum Genet. </span>1997;<span class="ref-vol">61</span>:60–7.</span> [<a href="/pmc/articles/PMC1715857/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1715857</span></a>] [<a href="/pubmed/9245985" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9245985</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.bernhardt.2012.604">Bernhardt BA, Zayac C, Trerotola SO, Asch DA, Pyeritz RE. Cost savings through molecular diagnosis for hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">Genet Med. </span>2012;<span class="ref-vol">14</span>:604–10.</span> [<a href="/pubmed/22281938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22281938</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.best.2011.358">Best DH, Vaughn C, McDonald J, Damjanovich K, Runo J, Chibuk J, Bayrak-Toydemir P. Mosaic ACVRL1 and ENG mutations in hereditary haemorrhagic telangiectasia patients. <span><span class="ref-journal">J Med Genet. </span>2011;<span class="ref-vol">48</span>:358–360.</span> [<a href="/pubmed/21378382" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21378382</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.bharatha.2012.72">Bharatha A, Faughnan ME, Kim H, Pourmohamad T, Krings T, Bayrak-Toydemir P, Pawlikowska L, McCulloch CE, Lawton MT, Dowd CF, Young WL, Terbrugge KG. Brain arteriovenous malformation multiplicity predicts the diagnosis of hereditary hemorrhagic telangiectasia: quantitative assessment. <span><span class="ref-journal">Stroke. </span>2012;<span class="ref-vol">43</span>:72–8.</span> [<a href="/pmc/articles/PMC3727386/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3727386</span></a>] [<a href="/pubmed/22034007" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22034007</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.bose.2009.2143">Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">N Engl J Med. </span>2009;<span class="ref-vol">360</span>:2143–4.</span> [<a href="/pubmed/19439755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19439755</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.bossler.2006.667">Bossler AD, Richards J, George C, Godmilow L, Ganguly A. Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype. <span><span class="ref-journal">Hum Mutat. </span>2006;<span class="ref-vol">27</span>:667–75.</span> [<a href="/pubmed/16752392" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16752392</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.boyer.2011.319">Boyer H, Fernandes P, Duran O, Hunter D, Goding G. Office-based sclerotherapy for recurrent epistaxis due to hereditary hemorrhagic telangiectasia: a pilot study. <span><span class="ref-journal">Int Forum Allergy Rhinol. </span>2011;<span class="ref-vol">1</span>:319–23.</span> [<a href="/pubmed/22287439" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22287439</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.brenard.2010.1253">Brenard R, Chapaux X, Deltenre P, Henrion J, De Maeght S, Horsmans Y, Borbath I, Leenaerts A, Van Cauter J, Francque S, Serst&#x000e9; T, Moreno C, Orlent H, Mengeot P, Lerut J, Sempoux C. Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia: the Belgian Registry based on 30 patients. <span><span class="ref-journal">Eur J Gastroenterol Hepatol. </span>2010;<span class="ref-vol">22</span>:1253–9.</span> [<a href="/pubmed/20631626" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20631626</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.brinkerhoff.2011.688">Brinkerhoff BT, Poetker DM, Choong NW. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">N Engl J Med. </span>2011;<span class="ref-vol">364</span>:688–9.</span> [<a href="/pubmed/21323562" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21323562</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.brusgaard.2004.556">Brusgaard K, Kjeldsen AD, Poulsen L, Moss H, Vase P, Rasmussen K, Kruse TA, H&#x000f8;rder M. Mutations in endoglin and in activin receptor-like kinase 1 among Danish patients with hereditary haemorrhagic telangiectasia. <span><span class="ref-journal">Clin Genet. </span>2004;<span class="ref-vol">66</span>:556–61.</span> [<a href="/pubmed/15521985" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15521985</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.buscarini.2004a.348">Buscarini E, Danesino C, Olivieri C, Lupinacci G, De Grazia F, Reduzzi L, Blotta P, Gazzaniga P, Pagella F, Grosso M, Pongiglione G, Buscarini L, Plauchu H, Zambelli A. Doppler ultrasonographic grading of hepatic vascular malformations in hereditary hemorrhagic telangiectasia -- results of extensive screening. <span><span class="ref-journal">Ultraschall Med. </span>2004a;<span class="ref-vol">25</span>:348–55.</span> [<a href="/pubmed/15368138" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15368138</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.buscarini.2004b.1089">Buscarini E, Danesino C, Plauchu H, de Fazio C, Olivieri C, Brambilla G, Menozzi F, Reduzzi L, Blotta P, Gazzaniga P, Pagella F, Grosso M, Pongiglione G, Cappiello J, Zambelli A. High prevalence of hepatic focal nodular hyperplasia in subjects with hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">Ultrasound Med Biol. </span>2004b;<span class="ref-vol">30</span>:1089–97.</span> [<a href="/pubmed/15550313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15550313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.buscarini.2011.2166">Buscarini E, Leandro G, Conte D, Danesino C, Daina E, Manfredi G, Lupinacci G, Brambilla G, Menozzi F, De Grazia F, Gazzaniga P, Inama G, Bonardi R, Blotta P, Forner P, Olivieri C, Perna A, Grosso M, Pongiglione G, Boccardi E, Pagella F, Rossi G, Zambelli A. Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia. <span><span class="ref-journal">Dig Dis Sci. </span>2011;<span class="ref-vol">56</span>:2166–78.</span> [<a href="/pmc/articles/PMC3112486/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3112486</span></a>] [<a href="/pubmed/21290179" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21290179</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.buscarini.2006.1040">Buscarini E, Plauchu H, Garcia Tsao G, White RI Jr, Sabb&#x000e0; C, Miller F, Saurin JC, Pelage JP, Lesca G, Marion MJ, Perna A, Faughnan ME. Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. <span><span class="ref-journal">Liver Int. </span>2006;<span class="ref-vol">26</span>:1040–6.</span> [<a href="/pubmed/17032403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17032403</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.chavan.2013.106">Chavan A, Schumann-Binarsch S, Luthe L, Nickau B, Els&#x000e4;sser A, K&#x000fc;hnel T, Geisthoff U, K&#x000f6;hne H. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT). <span><span class="ref-journal">Vasa. </span>2013;<span class="ref-vol">42</span>:106–10.</span> [<a href="/pubmed/23485837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23485837</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.cole.2005.577">Cole SG, Begbie ME, Wallace GM, Shovlin CL. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. <span><span class="ref-journal">J Med Genet. </span>2005;<span class="ref-vol">42</span>:577–82.</span> [<a href="/pmc/articles/PMC1736109/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1736109</span></a>] [<a href="/pubmed/15994879" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15994879</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.cottin.2007.361">Cottin V, Dupuis-Girod S, Lesca G, Cordier JF. Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (rendu-osler disease). <span><span class="ref-journal">Respiration. </span>2007;<span class="ref-vol">74</span>:361–78.</span> [<a href="/pubmed/17641482" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17641482</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.curie.2007.299">Curie A, Lesca G, Cottin V, Edery P, Bellon G, Faughnan ME, Plauchu H. Long-term follow-up in 12 children with pulmonary arteriovenous malformations: confirmation of hereditary hemorrhagic telangiectasia in all cases. <span><span class="ref-journal">J Pediatr. </span>2007;<span class="ref-vol">151</span>:299–306.</span> [<a href="/pubmed/17719943" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17719943</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.davidson.2010.432">Davidson TM, Olitsky SE, Wei JL. Hereditary hemorrhagic telangiectasia/avastin. <span><span class="ref-journal">Laryngoscope. </span>2010;<span class="ref-vol">120</span>:432–5.</span> [<a href="/pubmed/19998344" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19998344</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.devlin.2013.876">Devlin HL, Hosman AE, Shovlin CL. Antiplatlet and anticoagulant agents in hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">N Engl J Med. </span>2013;<span class="ref-vol">368</span>:876–8.</span> [<a href="/pubmed/23445111" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23445111</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.dupuisgirod.2012.948">Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Rivi&#x000e8;re S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H, Faure F. Bevacizumab in patients with HHT and severe hepatic vascular malformations and high cardiac output. <span><span class="ref-journal">JAMA. </span>2012;<span class="ref-vol">307</span>:948–55.</span> [<a href="/pubmed/22396517" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22396517</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.dupuisgirod.2010.340">Dupuis-Girod S, Chesnais AL, Ginon I, Dumortier J, Saurin JC, Finet G, Decullier E, Marion D, Plauchu H, Boillot O. Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study. <span><span class="ref-journal">Liver Transpl. </span>2010;<span class="ref-vol">16</span>:340–7.</span> [<a href="/pubmed/20209594" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20209594</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.dupuisgirod.2007.841">Dupuis-Girod S, Giraud S, Decullier E, Lesca G, Cottin V, Faure F, Merrot O, Saurin JC, Cordier JF, Plauchu H. Hemorrhagic hereditary telangiectasia (Rendu-Osler disease) and infectious diseases: an underestimated association. <span><span class="ref-journal">Clin Infect Dis. </span>2007;<span class="ref-vol">44</span>:841–5.</span> [<a href="/pubmed/17304458" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17304458</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.dupuisgirod.2016.934">Dupuis-Girod S, Ambrun A, Decullier E, Fargeton A-E, Roux A, Br&#x000e9;ant V, Colombet B, Rivi&#x000e8;re S, Cartier C, Lacombe P, Chinet R, Bilvet S, Blondel J-H, Gilvert-Dussardier B, Dufour X, Michel J, Harle J-R, Dessi P, Faure F. Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangiectasia: a randomized clinic trial. <span><span class="ref-journal">JAMA. </span>2016;<span class="ref-vol">316</span>:934–42.</span> [<a href="/pubmed/27599328" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27599328</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.eerola.2003.1240">Eerola I, Boon LM, Mulliken JB, Burrows PE, Dompmartin A, Watanabe S, Vanwijck R, Vikkula M. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. <span><span class="ref-journal">Am J Hum Genet. </span>2003;<span class="ref-vol">73</span>:1240–9.</span> [<a href="/pmc/articles/PMC1180390/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1180390</span></a>] [<a href="/pubmed/14639529" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14639529</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.faughnan.2011.73">Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J, Brown DH, Buscarini E, Chesnutt MS, Cottin V, Ganguly A, Gossage JR, Guttmacher AE, Hyland RH, Kennedy SJ, Korzenik J, Mager JJ, Ozanne AP, Piccirillo JF, Picus D, Plauchu H, Porteous ME, Pyeritz RE, Ross DA, Sabba C, Swanson K, Terry P, Wallace MC, Westermann CJ, White RI, Young LH, Zarrabeitia R. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. <span><span class="ref-journal">J Med Genet. </span>2011;<span class="ref-vol">48</span>:73–87.</span> [<a href="/pubmed/19553198" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19553198</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.faughnan.2004.826">Faughnan ME, Thabet A, Mei-Zahav M, Colombo M, Maclusky I, Hyland RH, Pugash RA, Chait P, Henderson KJ, White RI Jr. Pulmonary arteriovenous malformations in children: outcomes of transcatheter embolotherapy. <span><span class="ref-journal">J Pediatr. </span>2004;<span class="ref-vol">145</span>:826–31.</span> [<a href="/pubmed/15580209" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15580209</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.fernandezl.2007.254">Fernandez-L A, Garrido-Martin EM, Sanz-Rodriguez F, Ramirez JR, Morales-Angulo C, Zarrabeitia R, Perez-Molino A, Bernab&#x000e9;u C, Botella LM. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. <span><span class="ref-journal">Thromb Haemost. </span>2007;<span class="ref-vol">97</span>:254–62.</span> [<a href="/pubmed/17264955" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17264955</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.flanagan.2012.69">Flanagan BA, Collins C, Parra S. Intranasal tranexamic acid for the treatment of HHT: a case report and review of treatment options. <span><span class="ref-journal">Cutis. </span>2012;<span class="ref-vol">89</span>:69–72.</span> [<a href="/pubmed/22474728" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22474728</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.flieger.2006.631">Flieger D, Hainke S, Fischbach W. Dramatic improvement in HHT after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. <span><span class="ref-journal">Ann Hematol. </span>2006;<span class="ref-vol">85</span>:631–2.</span> [<a href="/pubmed/16807748" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16807748</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.fodstad.2011.611">Fodstad P, Dheyauldeen S, Rinde M, Bachmann-Harildstad G. Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe HHT. <span><span class="ref-journal">Ann Hematol. </span>2011;<span class="ref-vol">90</span>:611–2.</span> [<a href="/pmc/articles/PMC3070877/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3070877</span></a>] [<a href="/pubmed/20824275" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20824275</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.gallione.2010.333">Gallione C, Aylsworth AS, Beis J, Berk T, Bernhardt B, Clark RD, Clericuzio C, Danesino C, Drautz J, Fahl J, Fan Z, Faughnan M, Ganguly A, Garvie J, Henderson K, Kini U, Leedom T, Ludman M, Lux A, Maisenbacher M, Maxxucco S, Olivieri C, Ploos van Amstel JK, Prigoda-Lee N, Pyeritz RE, Reardon W, Vandeznade K, Wladman JD, White RI, Williams CA, Marchuk DA. Overlapping spectra of SMAD4 mutations in juvenile polyposis and JP-HHT syndrome. <span><span class="ref-journal">Am J Med Genet. </span>2010;<span class="ref-vol">152A</span>:333–9.</span> [<a href="/pubmed/20101697" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20101697</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.gallione.1998.286">Gallione CJ, Klaus DJ, Yeh EY, Stenzel TT, Xue Y, Anthony KB, McAllister KA, Baldwin MA, Berg JN, Lux A, Smith JD, Vary CP, Craigen WJ, Westermann CJ, Warner ML, Miller YE, Jackson CE, Guttmacher AE, Marchuk DA. Mutation and expression analysis of the endoglin gene in hereditary hemorrhagic telangiectasia reveals null alleles. <span><span class="ref-journal">Hum Mutat. </span>1998;<span class="ref-vol">11</span>:286–94.</span> [<a href="/pubmed/9554745" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9554745</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.gallione.2004.852">Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, Mitchell G, Drouin E, Westermann CJ, Marchuk DA. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). <span><span class="ref-journal">Lancet. </span>2004;<span class="ref-vol">363</span>:852–9.</span> [<a href="/pubmed/15031030" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15031030</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.gallione.2006.793">Gallione CJ, Richards JA, Letteboer TG, Rushlow D, Prigoda NL, Leedom TP, Ganguly A, Castells A, Ploos van Amstel JK, Westermann CJ, Pyeritz RE, Marchuk DA. SMAD4 mutations found in unselected HHT patients. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:793–7.</span> [<a href="/pmc/articles/PMC2563178/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2563178</span></a>] [<a href="/pubmed/16613914" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16613914</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.garciatsao.2000.931">Garcia-Tsao G, Korzenik JR, Young L, Henderson KJ, Jain D, Byrd B, Pollak JS, White RI Jr. Liver disease in patients with hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">N Engl J Med. </span>2000;<span class="ref-vol">343</span>:931–6.</span> [<a href="/pubmed/11006369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11006369</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.gedge.2007.258">Gedge F, McDonald J, Phansalkar A, Chou LS, Calderon F, Mao R, Lyon E, Bayrak-Toydemir P. Clinical and analytical sensitivities in hereditary hemorrhagic telangiectasia testing and a report of de novo mutations. <span><span class="ref-journal">J Mol Diagn. </span>2007;<span class="ref-vol">9</span>:258–65.</span> [<a href="/pmc/articles/PMC1867450/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1867450</span></a>] [<a href="/pubmed/17384219" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17384219</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.girerd.2010.851">Girerd B, Montani D, Coulet F, Sztrymf B, Yaici A, Ja&#x000ef;s X, Tregouet D, Reis A, Drouin-Garraud V, Fraisse A, Sitbon O, O'Callaghan DS, Simonneau G, Soubrier F, Humbert M. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2010;<span class="ref-vol">181</span>:851–61.</span> [<a href="/pubmed/20056902" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20056902</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.gr_ve.2010.760">Gr&#x000e8;ve E, Moussata D, Gaudin JL, Lapalus MG, Giraud S, Dupuis-Girod S, Calender A, Plauchu H, Saurin JC. High diagnostic and clinical impact of small-bowel capsule endoscopy in patients with hereditary hemorrhagic telangiectasia with overt digestive bleeding and/or severe anemia. <span><span class="ref-journal">Gastrointest Endosc. </span>2010;<span class="ref-vol">71</span>:760–7.</span> [<a href="/pubmed/20170910" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20170910</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.guldmann.2012.953">Guldmann R, Dupret A, Nivoix Y, Schultz P, Debry Cl. Bevacizumab nasal spray: noninvasive treatment of epistaxis in patients with Rendu-Olser disease. <span><span class="ref-journal">Laryngoscope. </span>2012;<span class="ref-vol">122</span>:953–5.</span> [<a href="/pubmed/22447341" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22447341</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.guttmacher.2013">Guttmacher AE, Marchuck D, Trerotola SO, Pyeritz RE. Hereditary hemorrhagic telangiectasia. In: Rimoin DL, Pyeritz RE, Korf BR, eds. <em>Emery and Rimoin's Principles and Practice of Medical Genetics</em>. 6 ed. Chap 49. Academic Press; 2013.</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.hetts.2014.1376">Hetts SW, Cooke DL, Nelson J, Gupta N, Fullerton H, Amans MR, Narvid JA, Moftakhar P, McSwain H, Dowd CF, Higashida RT, Halbach VV, Lawton MT, Kim H. Influence of patient age on angioarchitecture of brain arteriovenous malformations. <span><span class="ref-journal">Am J Neuroradiol. </span>2014;<span class="ref-vol">35</span>:1376–80.</span> [<a href="/pmc/articles/PMC4102659/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4102659</span></a>] [<a href="/pubmed/24627452" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24627452</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.howe.2004.484">Howe JR, Sayed MG, Ahmed AF, Ringold J, Larsen-Haidle J, Merg A, Mitros FA, Vaccaro CA, Petersen GM, Giardiello FM, Tinley ST, Aaltonen LA, Lynch HT. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:484–91.</span> [<a href="/pmc/articles/PMC1735829/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735829</span></a>] [<a href="/pubmed/15235019" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15235019</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.ianora.2004.250">Ianora AA, Memeo M, Sabba C, Cirulli A, Rotondo A, Angelelli G. Hereditary hemorrhagic telangiectasia: multi-detector row helical CT assessment of hepatic involvement. <span><span class="ref-journal">Radiology. </span>2004;<span class="ref-vol">230</span>:250–9.</span> [<a href="/pubmed/14645886" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14645886</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.jameson.2004.705">Jameson JJ, Cave DR. Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">Laryngoscope. </span>2004;<span class="ref-vol">114</span>:705–9.</span> [<a href="/pubmed/15064628" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15064628</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.kjeldsen.2000.415">Kjeldsen AD, Kjeldsen J. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">Am J Gastroenterol. </span>2000;<span class="ref-vol">95</span>:415–8.</span> [<a href="/pubmed/10685743" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10685743</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.kjeldsen.2005.349">Kjeldsen AD, M&#x000f8;ller TR, Brusgaard K, Vase P, Andersen PE. Clinical symptoms according to genotype amongst patients with hereditary haemorrhagic telangiectasia. <span><span class="ref-journal">J Intern Med. </span>2005;<span class="ref-vol">258</span>:349–55.</span> [<a href="/pubmed/16164574" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16164574</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.lacout.2010.479">Lacout A, Pelage JP, Lesur G, Chinet T, Beauchet A, Roume J, Lacombe P. Pancreatic involvement in hereditary hemorrhagic telangiectasia: assessment with multidetector helical CT. <span><span class="ref-journal">Radiology. </span>2010;<span class="ref-vol">254</span>:479–84.</span> [<a href="/pubmed/20093519" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20093519</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.lebrin.2010.420">Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, Br&#x000e9;ant C, Mathivet T, Larriv&#x000e9;e B, Thomas JL, Arthur HM, Westermann CJ, Disch F, Mager JJ, Snijder RJ, Eichmann A, Mummery CL. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">Nat Med. </span>2010;<span class="ref-vol">16</span>:420–8.</span> [<a href="/pubmed/20364125" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20364125</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.lee.2010.3059">Lee M, Sze DY, Bonham CA, Daugherty TJ. Hepatic arteriovenous malformations from hereditary hemorrhagic telangiectasia: treatment with liver transplantation. <span><span class="ref-journal">Dig Dis Sci. </span>2010;<span class="ref-vol">55</span>:3059–62.</span> [<a href="/pubmed/20844961" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20844961</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.lenato.2006.213">Lenato GM, Lastella P, Di Giacomo MC, Resta N, Suppressa P, Pasculli G, Sabb&#x000e0; C, Guanti G. DHPLC-based mutation analysis of ENG and ALK-1 genes in HHT Italian population. <span><span class="ref-journal">Hum Mutat. </span>2006;<span class="ref-vol">27</span>:213–4.</span> [<a href="/pubmed/16429404" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16429404</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.lerut.2006.854">Lerut J, Orlando G, Adam R, Sabb&#x000e0; C, Pfitzmann R, Klempnauer J, Belghiti J, Pirenne J, Thevenot T, Hillert C, Brown CM, Gonze D, Karam V, Boillot O, et al.  Liver transplantation for hereditary hemorrhagic telangiectasia: Report of the European liver transplant registry. <span><span class="ref-journal">Ann Surg. </span>2006;<span class="ref-vol">244</span>:854–62.</span> [<a href="/pmc/articles/PMC1856634/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1856634</span></a>] [<a href="/pubmed/17122610" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17122610</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.lesca.2006.598">Lesca G, Burnichon N, Raux G, Tosi M, Pinson S, Marion MJ, Babin E, Gilbert-Dussardier B, Rivi&#x000e8;re S, Goizet C, Faivre L, Plauchu H, Fr&#x000e9;bourg T, Calender A, Giraud S, et al.  Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients. <span><span class="ref-journal">Hum Mutat. </span>2006;<span class="ref-vol">27</span>:598.</span> [<a href="/pubmed/16705692" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16705692</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.lesca.2007.14">Lesca G, Olivieri C, Burnichon N, Pagella F, Carette MF, Gilbert-Dussardier B, Goizet C, Roume J, Rabilloud M, Saurin JC, Cottin V, Honnorat J, Coulet F, Giraud S, Calender A, Danesino C, Buscarini E, Plauchu H, et al.  Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. <span><span class="ref-journal">Genet Med. </span>2007;<span class="ref-vol">9</span>:14–22.</span> [<a href="/pubmed/17224686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17224686</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.letteboer.2006.371">Letteboer TG, Mager JJ, Snijder RJ, Koeleman BP, Lindhout D, Ploos van Amstel JK, Westermann CJ. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:371–7.</span> [<a href="/pmc/articles/PMC2563220/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2563220</span></a>] [<a href="/pubmed/16155196" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16155196</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.letteboer.2005.8">Letteboer TG, Zewald RA, Kamping EJ, de Haas G, Mager JJ, Snijder RJ, Lindhout D, Hennekam FA, Westermann CJ, Ploos van Amstel JK. Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients. <span><span class="ref-journal">Hum Genet. </span>2005;<span class="ref-vol">116</span>:8–16.</span> [<a href="/pubmed/15517393" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15517393</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.marchuk.1998.269">Marchuk DA, Guttmacher AE, Penner JA, Ganguly P. Report on the workshop on Hereditary Hemorrhagic Telangiectasia, July 10-11, 1997. <span><span class="ref-journal">Am J Med Genet. </span>1998;<span class="ref-vol">76</span>:269–73.</span> [<a href="/pubmed/9508248" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9508248</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.mcdonald.2011a.607">McDonald J, Bayrak-Toydemir P, Pyeritz RE. Hereditary hemorrhagic telangiectasia: An overview of diagnosis, management and pathogenesis. <span><span class="ref-journal">Genet Med. </span>2011a;<span class="ref-vol">13</span>:607–16.</span> [<a href="/pubmed/21546842" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21546842</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.mcdonald.2011b.335">McDonald J, Damjanovich K, Millson A, Wooderchak W, Chibuk JM, Stevenson DA, Gedge F, Bayrak-Toydemir P. Molecular diagnosis in hereditary hemorrhagic telangiectasia: findings in a series tested simultaneously by sequencing and deletion/duplication analysis. <span><span class="ref-journal">Clin Genet. </span>2011b;<span class="ref-vol">79</span>:335–44.</span> [<a href="/pubmed/21158752" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21158752</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.mcdonald.2015.1">McDonald J, Wooderchak-Donahue W, VanSant Webb C, Whitehead K, Stevenson DA, Bayrak-Toydemir P. Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. <span><span class="ref-journal">Front Genet. </span>2015;<span class="ref-vol">6</span>:1.</span> [<a href="/pmc/articles/PMC4306304/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4306304</span></a>] [<a href="/pubmed/25674101" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25674101</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.meizahav.2006.596">Mei-Zahav M, Letarte M, Faughnan ME, Abdalla SA, Cymerman U, MacLusky IB. Symptomatic Children with Hereditary Hemorrhagic Telangiectasia. <span><span class="ref-journal">Arch Pediatr Adolesc Med. </span>2006;<span class="ref-vol">160</span>:596–601.</span> [<a href="/pubmed/16754821" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16754821</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.mitchell.2008.210">Mitchell A, Adams LA, MacQuillan G, Tibballs J. vanden Driesen R, Delriviere L. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">Liver Transpl. </span>2008;<span class="ref-vol">14</span>:210–3.</span> [<a href="/pubmed/18236396" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18236396</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.mohler.2009.356">Mohler ER III, Doriswamy V, Sibley A, Bernhardt BA, Pyeritz RE. Transillumination of the fingers for vascular anomalies: a novel method for evaluating hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">Genet Med. </span>2009;<span class="ref-vol">11</span>:356–8.</span> [<a href="/pubmed/19365270" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19365270</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.morais.2012.80">Morais D, Mill&#x000e1;s T, Zarrabeitia R, Botella LM, Almaraz A. Local sclerotherapy with Polydocanol for the treatment of Epistaxis in HHT: 15 years of experience. <span><span class="ref-journal">Rhinology. </span>2012;<span class="ref-vol">50</span>:80–6.</span> [<a href="/pubmed/22469609" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22469609</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.morgan.2002.e12">Morgan T, McDonald J, Anderson C, Ismail M, Miller F, Mao R, Madan A, Barnes P, Hudgins L, Manning M. Intracranial hemorrhage in infants and children with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome). <span><span class="ref-journal">Pediatrics. </span>2002;<span class="ref-vol">109</span>:E12.</span> [<a href="/pubmed/11773580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11773580</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.nawaz.2008.1582">Nawaz A, Litt HI, Stavropoulos SW, Charagundla SR, Shlansky-Goldberg RD, Freiman DB, Chittams J, Pyeritz RE, Trerotola SO. Digital subtraction pulmonary arteriography versus multidetector CT in the detection of pulmonary arteriovenous malformations. <span><span class="ref-journal">J Vasc Interv Radiol. </span>2008;<span class="ref-vol">19</span>:1582–8.</span> [<a href="/pubmed/18774307" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18774307</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.olitsky.2012.375">Olitsky SE. Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">Am J Otolaryngol. </span>2012;<span class="ref-vol">33</span>:375–6.</span> [<a href="/pubmed/22079094" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22079094</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.olivieri.2007.820">Olivieri C, Pagella F, Semino L, Lanzarini L, Valacca C, Pilotto A, Corno S, Scappaticci S, Manfredi G, Buscarini E, Danesino C. Analysis of ENG and ACVRL1 genes in 137 HHT Italian families identifies 76 different mutations (24 novel). Comparison with other European studies. <span><span class="ref-journal">J Hum Genet. </span>2007;<span class="ref-vol">52</span>:820–9.</span> [<a href="/pubmed/17786384" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17786384</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.omalley.2012.886">O'Malley M, LaGuardia L, Kalady MF, Parambil J, Heald B, Eng C, Church J, Burke CA. The prevalence of hereditary hemorrhagic telangiectasia in juvenile polyposis syndrome. <span><span class="ref-journal">Dis Colon Rectum. </span>2012;<span class="ref-vol">55</span>:886–92.</span> [<a href="/pubmed/22810475" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22810475</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.suppressa.2011.365">Suppressa P, Liso A, Sabb&#x000e0; C. Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia. <span><span class="ref-journal">Br J Haematol. </span>2011;<span class="ref-vol">152</span>:365.</span> [<a href="/pubmed/21265821" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21265821</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.pece.1997.2568">Pece N, Vera S, Cymerman U, White RI Jr, Wrana JL, Letarte M. Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative. <span><span class="ref-journal">J Clin Invest. </span>1997;<span class="ref-vol">100</span>:2568–79.</span> [<a href="/pmc/articles/PMC508458/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC508458</span></a>] [<a href="/pubmed/9366572" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9366572</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.plauchu.1989.291">Plauchu H, de Chadar&#x000e9;vian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. <span><span class="ref-journal">Am J Med Genet. </span>1989;<span class="ref-vol">32</span>:291–7.</span> [<a href="/pubmed/2729347" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2729347</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.porteous.1992.527">Porteous ME, Burn J, Proctor SJ. Hereditary haemorrhagic telangiectasia: a clinical analysis. <span><span class="ref-journal">J Med Genet. </span>1992;<span class="ref-vol">29</span>:527–30.</span> [<a href="/pmc/articles/PMC1016055/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1016055</span></a>] [<a href="/pubmed/1518020" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1518020</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.prigoda.2006.722">Prigoda NL, Savas S, Abdalla SA, Piovesan B, Rushlow D, Vandezande K, Zhang E, Ozcelik H, Gallie BL, Letarte M. Hereditary haemorrhagic telangiectasia: mutation detection, test sensitivity and novel mutations. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:722–8.</span> [<a href="/pmc/articles/PMC2564570/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2564570</span></a>] [<a href="/pubmed/16690726" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16690726</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.proctor.2008.756">Proctor DD, Henderson KJ, Dziura JD, White RI Jr. Hormonal therapy for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">J Clin Gastroenterol. </span>2008;<span class="ref-vol">42</span>:756–7.</span> [<a href="/pubmed/18496387" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18496387</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.reh.2013.820">Reh DD, Hur K, Merlo CA. Efficacy of a topical sesame/rose geranium oil compound in patients with hereditary hemorrhagic telangiectasia associated epistaxis. <span><span class="ref-journal">Laryngoscope. </span>2013;<span class="ref-vol">123</span>:820–2.</span> [<a href="/pubmed/23401038" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23401038</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.revencu.2013a.1632">Revencu N, Boon LM, Mendola A, Cordisco MR, Dubois J, Clapuyt P, Hammer F, Amor DJ, Irvine AD, Baselga E, Dompmartin A, Syed S, Martin-Santiago A, Ades L, Collins F, Smith J, Sandaradura S, Barrio VR, Burrows PE, Blei F, Cozzolino M, Brunetti-Pierri N, Vicente A, Abramowicz M, D&#x000e9;sir J, Vilain C, Chung WK, Wilson A, Gardiner CA, Dwight Y, Lord DJ, Fishman L, Cytrynbaum C, Chamlin S, Ghali F, Gilaberte Y, Joss S, Boente Mdel C, L&#x000e9;aut&#x000e9;-Labr&#x000e8;ze C, Delrue MA, Bayliss S, Martorell L, Gonz&#x000e1;lez-Ense&#x000f1;at MA, Mazereeuw-Hautier J, O'Donnell B, Bessis D, Pyeritz RE, Salhi A, Tan OT, Wargon O, Mulliken JB, Vikkula M. RASA1 mutations and associated phenotypes in 68 families with capillary malformation-arteriovenous malformations. <span><span class="ref-journal">Hum Mutat. </span>2013a;<span class="ref-vol">34</span>:1632–41.</span> [<a href="/pubmed/24038909" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24038909</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.revencu.b">Revencu N, Boon LM, Vikkula M. Capillary malformation/arteriovenous malformation. In: Rimoin DL, Pyeritz RE, Korf BR, eds. <em>Emery and Rimoin's Principles and Practice of Medical Genetics</em>. 6 ed. Chap 57. Academic Press; 2013b.</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.richer.2012.401">Richer SL, Geisthoff UW, Livada N, Ward PD, Johnson L, Mainka A, Henderson KJ, Maune S, White RI Jr, Ross DA. The Young's procedure for severe epistaxis from HHT. <span><span class="ref-journal">Am J Rhinol Allergy. </span>2012;<span class="ref-vol">26</span>:401–4.</span> [<a href="/pubmed/23168156" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23168156</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.richardsyutz.2010.61">Richards-Yutz J, Grant K, Chao EC, Walther SE, Ganguly A. Update on molecular diagnosis of hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">Hum Genet. </span>2010;<span class="ref-vol">128</span>:61–77.</span> [<a href="/pubmed/20414677" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20414677</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.rigelsky.2008.2551">Rigelsky CM, Jennings C, Lehtonen R, Minai OA, Eng C, Aldred MA. BMPR2 mutation in a patient with pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">Am J Med Genet A. </span>2008;<span class="ref-vol">146A</span>:2551–6.</span> [<a href="/pubmed/18792970" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18792970</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.schulte.2005.595">Schulte C, Geisthoff U, Lux A, Kupka S, Zenner HP, Blin N, Pfister M. High frequency of ENG and ALK1/ACVRL1 mutations in German HHT patients. <span><span class="ref-journal">Hum Mutat. </span>2005;<span class="ref-vol">25</span>:595.</span> [<a href="/pubmed/15880681" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15880681</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.shovlin.2000.66">Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). <span><span class="ref-journal">Am J Med Genet. </span>2000;<span class="ref-vol">91</span>:66–7.</span> [<a href="/pubmed/10751092" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10751092</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.soubrier.2013.d13">Soubrier F, Chung WK, Machado R, Gr&#x000fc;nig E, Aldred M, Geraci M, Loyd JE, Elliott CG, Trembath RC, Newman JH, Humbert M. Genetics and Genomics of Pulmonary Arterial Hypertension. <span><span class="ref-journal">J Am Coll Cardiol. </span>2013;<span class="ref-vol">62</span>:D13–21.</span> [<a href="/pubmed/24355637" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24355637</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.thompson.2014.91">Thompson AB, Ross DA, Berard P, Figueroa-Bodine J, Livada N, Richer SL. Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">Allergy Rhinol (Providence). </span>2014;<span class="ref-vol">5</span>:91–5.</span> [<a href="/pmc/articles/PMC4124584/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4124584</span></a>] [<a href="/pubmed/25199101" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25199101</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.trerotola.2010.837">Trerotola SO, Pyeritz RE. PAVM embolization: an update. <span><span class="ref-journal">AJR Am J Roentgenol. </span>2010;<span class="ref-vol">195</span>:837–45.</span> [<a href="/pubmed/20858807" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20858807</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.wain.2014.588">Wain KE, Ellingson MS, McDonald J, Gammon A, Roberts M, Pichurin P, Winship I, Riegert-Johnson DL, Weitzel JN, Lindor NM. Appreciating the broad clinical features of SMAD4 mutation carriers: a multicenter chart review. <span><span class="ref-journal">Genet Med. </span>2014;<span class="ref-vol">16</span>:588–93.</span> [<a href="/pmc/articles/PMC4125531/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4125531</span></a>] [<a href="/pubmed/24525918" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24525918</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.white.1996.2627">White RI Jr. Pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: embolotherapy using balloons and coils. <span><span class="ref-journal">Arch Intern Med. </span>1996;<span class="ref-vol">156</span>:2627–8.</span> [<a href="/pubmed/8951309" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8951309</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.whitehead.2016.943">Whitehead KJ, Sautter NB, McWilliams JP, Chakinala MM, Merlo CA, Johnson MH, James M, Everett EM, Clancy MS, Faughnan ME, Oh SP, Olitsky SE, Pyeritz RE, Gossage JR. Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial. <span><span class="ref-journal">JAMA. </span>2016;<span class="ref-vol">316</span>:943–51.</span> [<a href="/pubmed/27599329" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27599329</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.wooderchakdonahue.2013.530">Wooderchak-Donahue WL, McDonald J, O'Fallon B, Upton PD, Li W, Roman BL, Young S, Plant P, F&#x000fc;l&#x000f6;p GT, Langa C, Morrell NW, Botella LM, Bernabeu C, Stevenson DA, Runo JR, Bayrak-Toydemir P. BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. <span><span class="ref-journal">Am J Hum Genet. </span>2013;<span class="ref-vol">93</span>:530–7.</span> [<a href="/pmc/articles/PMC3769931/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3769931</span></a>] [<a href="/pubmed/23972370" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23972370</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hht.REF.yaniv.2009.284">Yaniv E, Preis M, Hadar T, Shvero J, Haddad M. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. <span><span class="ref-journal">Laryngoscope. </span>2009;<span class="ref-vol">119</span>:284–8.</span> [<a href="/pubmed/19160429" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19160429</span></a>]</div></li></ul></div></div><div id="hht.Chapter_Notes"><h2 id="_hht_Chapter_Notes_">Chapter Notes</h2><div id="hht.Acknowledgments"><h3>Acknowledgments</h3><p>Robert I White, MD<br />School of Medicine, Yale University</p><p>Alan Guttmacher, MD<br />National Human Genome Research Institute, National Institutes of Health</p></div><div id="hht.Author_History"><h3>Author History</h3><p>Alan Guttmacher, MD; National Institutes of Health (2000-2009) <br />Jamie McDonald, MS, CGC (2000-present) <br />Reed E Pyeritz, MD, PhD, FACMG (2009-present)</p></div><div id="hht.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>2 February 2017 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>24 July 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 January 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 May 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 November 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>16 March 2004 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a></div></li><li class="half_rhythm"><div>26 February 2004 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a> added as a test method</div></li><li class="half_rhythm"><div>4 August 2003 (cd) Revisions</div></li><li class="half_rhythm"><div>17 June 2003 (ca) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 June 2000 (me) Review posted live</div></li><li class="half_rhythm"><div>January 2000 (jm) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1351</span><span class="label">PMID: <a href="/pubmed/20301525" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301525</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/deafness-overview/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hlrcc/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1351&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1351/?report=reader">PubReader</a></li><li><a href="/books/NBK1351/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1351" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1351" style="display:none" title="Cite this Page"><div class="bk_tt">McDonald J, Pyeritz RE. Hereditary Hemorrhagic Telangiectasia. 2000 Jun 26 [Updated 2017 Feb 2]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1351/pdf/Bookshelf_NBK1351.pdf">PDF version of this page</a> (529K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#hht.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#hht.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#hht.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#hht.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#hht.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#hht.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#hht.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#hht.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#hht.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#hht.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#hht.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2022[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ENG</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2658[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">GDF2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=94[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ACVRL1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4089[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SMAD4</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1499966" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1499966" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1499966" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1499966" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301642" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Juvenile Polyposis Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Juvenile Polyposis Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Larsen Haidle J, Howe JR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30075565" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Clinical features and treatment of hereditary hemorrhagic telangiectasia.</a><span class="source">[Medicine (Baltimore). 2018]</span><div class="brieflinkpop offscreen_noflow">Clinical features and treatment of hereditary hemorrhagic telangiectasia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Li S, Wang SJ, Zhao YQ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Medicine (Baltimore). 2018 Aug; 97(31):e11687. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/16754821" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Symptomatic children with hereditary hemorrhagic telangiectasia: a pediatric center experience.</a><span class="source">[Arch Pediatr Adolesc Med. 2006]</span><div class="brieflinkpop offscreen_noflow">Symptomatic children with hereditary hemorrhagic telangiectasia: a pediatric center experience.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mei-Zahav M, Letarte M, Faughnan ME, Abdalla SA, Cymerman U, MacLusky IB. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Arch Pediatr Adolesc Med. 2006 Jun; 160(6):596-601. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28603431" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary hemorrhagic telangiectasia and pregnancy: potential adverse events and pregnancy outcomes.</a><span class="source">[Int J Womens Health. 2017]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary hemorrhagic telangiectasia and pregnancy: potential adverse events and pregnancy outcomes.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bari O, Cohen PR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Int J Womens Health. 2017; 9:373-378. Epub 2017 May 26.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301658" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Heritable Pulmonary Arterial Hypertension</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Heritable Pulmonary Arterial Hypertension<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Austin ED, Loyd JE, Phillips JA III. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301525" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301525" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc8e5639a66ee2ba790110">Hereditary Hemorrhagic Telangiectasia - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Hereditary Hemorrhagic Telangiectasia - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T04:03:18-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE89FE00DFC8546100000000049E0239&amp;ncbi_session=CE89FE00DFC8E551_1182SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1351%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1351&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1351/&amp;ncbi_pagename=Hereditary Hemorrhagic Telangiectasia - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE89FE00DFC8E551_1182SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>